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ABSTRACT 
This dissertation is an effort to further define the central relationship of oxytocin 
(OT) and relaxin. The enclosed experiments have used rats and pigs to study this 
relationship. 
The first study looked at the effect of relaxin on the secretion of oxytocin and 
prolactin in pregnant gilts. Intravenous administration of relaxin appeared to mildly 
increase the circulating oxytocin and prolactin in pigs at midgestation, but had no effect in 
late gestational gilts. However, removal of endogenous relaxin in late gestational gilts did 
cause a large secretion of oxytocin and a mild release of prolactin, followed by a rapid 
return to baseline values for both hormones. This may indicate that relaxin acts to prevent 
the premature release of oxytocin in late gestation. 
The second study looked at the effect of relaxin on the activity of oxytocinergic 
cells in the hypothalamus of late pregnant rats following intravenous administration of 
relaxin. Cellular activation was visualized using the immunohistochemical labeling of Fos 
as a marker. In animals which received relaxin, Fos-like immunoreactivity was increased 
over that in animals which received vehicle. The increased Fos-like immunoreactivity was 
found in the supraoptic nucleus (SON), paraventricular nucleus (PVN) and subfornical 
organ. The Fos-like immunoreactivity in the SON and PVN was co-localized in cells 
exhibiting oxytocin-like immunoreactivity. This suggests that relaxin is changing the 
cellular activity within oxytocinergic cells. 
vu 
The third study goes on the determine if the activity seen following relaxin 
administration within oxytocinergic cells of late pregnant rats, is an increase in the 
synthesis of oxytocin. In situ hybridization was used to compare levels of oxytocin mRNA 
within the SON and PVN between rats exposed to endogenous or exogenous relaxin and 
those with no circulating relaxin. No differences were seen in the amount of oxytocin 
mRNA present as a result of the presence or absence of relaxin in the circulation. 
Collectively, the results from these studies indicate that relaxin affects the release of 
oxytocin during pregnancy. Relaxin probably does this by changing activity at the level of 
the cell body, but the rate of synthesis of oxytocin is unchanged. 
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CHAPTER 1 
GENERAL INTRODUCTION 
Introduction 
The phenomenon ot parturition is ^"ell studied and yet is not fully understood. 
The interaction of hormones culminating in birth has become less of a mystery over the 
last half centurv: however, the search goes on tor a complete explanation to this awesome 
event. 
It is well known that oxvtocin (OT) plays an important role in the expulsion of the 
fetus. Its release during parturition is selt-controlled through a positive feed back loop 
(Faike, 1989). But, what prevents it trom being released prematurely? Endogenous opioids 
appear to inhibit the release o f OT (Lindow et al.. 1996; Douglas et al., 1993), but there 
may be another player. Relaxin, a polvpeptide hormone whose primary role m parturition 
is to prepare the reproductive tract tor tetal expulsion bv remodeling its collagen, has been 
found to interact centrallv with oxvtocin. This dissertation focuses on gaining a more 
complete understanding ot the interrelationship between OT and relaxin. 
Oxvtocin IS a small peptide made pnmarilv in the brain. It is also made in the 
placenta and uterus (Letebvre et al., 1992) of the rat close to term, and in the cow, OT is 
found in the corpc^ra luiea (CL) during pregnancv (Guldenaar et al., 1984); however, this 
discussion is limited to its location in the brain. Oxvtocin is translated with a co-expressed 
protein, neurophysin (Morris, 1976), in magnocellular neurons of the supraoptic (SON) 
and paraventricular nuclei (P\ N') within the hypothalamus. Following post-translational 
processing, oxvtocin is comprised of 9 amino acid residues and a disulfide bond. In the 
neuron cell bodv. it is then packaged in neurosecretory vesicles for axonal transport to the 
neurohypophysis (For review see Gainer and Wray, 1994). From there it can be released 
into the circulation tollowing neuronal depolarization. 
Oxvtocin moderates several body functions, the most notable of which are 
involved in reproductive phvsiologv. The putative oxytocin was named for its ability to 
hasten childbirth (Ott and Scott, 19C9); oxy meaning quick and toco denoting birth. It is 
the most powerful uterotonic agent known. However, like all hormones, it acts through 
Its receptor, and it its receptor is not expressed in the uterus, it cannot act to mcrease 
myometrial contractions. Oxvtocin is also responsible for milk letdown. Oxytocin 
receptors are upreguLued in the uterus on the day of parturition (Alexandrova and Soloff, 
1980) and in the mammarv gland immediatelv following parturition (Lundin-Schiller et 
al., 1996). Oxytocin has also been implicated as an osmoregulator, due to its response to 
slight variation^ in the plasma osmolalitv ot rats (LeiVIoine and Young, 1992). It has also 
been found to enhance natnuresis (Bourque, et al., 1994). These responses are thought to 
be mediated bv the circumventncular organs which have neurons sending axons to 
synapse on magnoceilular neurons ot the SON and PVN. 
Oxytocin has been implicated as a releasing factor for prolactin (PRL). Prolactin is 
mammotrophic, and in some species is also luteotrophic. Prolactin acts at the mammary 
gland to increase the production of casein and a-lactalbumin. Interestingly, relaxin has 
been shown to increase the release ot PRL in vitro (Sortino et al., 1989) from cultured 
cycling-female rat adenohypophyses and in i-ivo following intracerebroventricular (i.e.v.) 
administration to pseudopregnant pigs (Li et al., 1993) . Because OT is a hypothetical PRL 
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releasing factor, it is possible that relaxm s effect on the release of PRL is mediated through 
a release of oxytocin. But. Porter et al. (1992), demonstrated that relaxin did not have an 
effect on the release of OT from cultured cycling-sow neurohypophyses, or from lactating 
sows administered relaxin intravenously. And, relaxin suppressed the release of OT from 
cultured bovine luteal cells (Musah, et al., 199C). However, no in vivo studies have been 
completed to look at the effect ot relaxin on the release or synthesis of oxytocin in 
pregnant pigs, in which PRL levels have been shown to be elevated following relaxin 
administration (L.i et al., 1993). 
The release ot OT is controlled electrophysiologically, but is modulated by 
stimulatory and inhibitory lactors. Electrophysiologically, the release of OT depends on 
the physiologic state ot the animal. Oxytocin is released in increased levels during 
parturition and lactation, and also in response to dehydration. During times of 
background acti\ u\. OT neurons have a slow irregular or fast continuous pattern and 
average 1 spike/second (Poulain and Wakerlev, 1982). The electrophysiology of OTergic 
neurons during suckling is well studied. Spinal atferents from the nipples synapse on 
OTergic cells (Poulain, 1983) producing a characteristic high frequency discharge of action 
potentials (Poulain and Wakerley, 1982) leading to the release of a bolus of oxytocin from 
the neurohypophysis (Gainer and XX'ray, 1994). Oxytocin then acts on the myoepithelial 
cells in the mammar\' gland to cause an ejection ot milk. During parturition, the firing rate 
of OTergic cells is increased and undergoes bursts of high frequency firing which are 
correlated to uterine contractions (Poulain and Wakerlev, 1982), and OT is released in 
boluses during fetal expulsion (Summerlee, 1981). Dehydration causes the mean firing rate 
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of OTergic neurons to triple, but the pattern continues in the slow irregular or fast 
continuous fashion tvpical ot these neurons. 
The release of OT is also controlled by the presence of inhibitory and stimulatory 
factors. Oxytocin has a positive ettect on its own release both in the hypothalamus 
(Theodosis, 1985) and at the level ol the neurohypophysis (Falke, 1989). During 
parturition, the Ferguson retle.x (increased release of OT following vaginal distention) is 
probably acting to enhance this positive feedback system. It is also postulated that estrogen 
facilitates the rele,ise ot OT during mating (Hadley, 1992). Inhibitory control over the 
release of OT seems to be a function ot opioids. Administration of naloxone, an opioid 
anatagonist. to neural lobes increased the electrically stimulated release of OT; however, 
this was more pronounced in nonpregnant rats than in late pregnant rats (Douglas et al., 
1993). Dynorphin, which is synthesized by vasopressinergic cells (Meister et al., 1990; 
Bondy et al., 1989) inhibits the electrically stimulated release of OT (Douglas et al, 1993). 
This effect is also seen on the release ot OT trom its dendrites m the hypothalamus 
(Ingram et al.. 1996). There is also a reciprocal relationship between OT and p-endorphin 
release in late pregnant humans (Lindow et al, 1996). Interestingly, it appears that relaxin 
may be playing a role in developing increased opioid tone in late pregnancy (Way et al., 
1993). 
Control ot the synthesis ot o.wtocin has not been as thoroughly studied as control 
over its release. Estrogen has been shown to modulate OT mRNA (Richard and Zingg, 
1990) through an estrogen response element located in the oxytocin gene promoter. And, 
like the regulation ot the release ot OT during pregnancy, its synthesis may also be 
controlled bv opioids (Douglas et al., 1994). The role of relaxin as a potential player is 
being investigated. 
Rela.xin is a polypeptide hormone which is primarily made in reproductive organs. 
The pnmarv site ot rela.xin production vanes with species. It is a member of the family of 
insulin-like growth factors, weighs 60CC daltons, is structurally similar to insulin, and is 
found in species ranging from the sand shark to the human; however, there is some 
question regarding its significance in ruminants (Bathgate et al.. 1996; Hartung et al., 1995, 
Roche et al., 1993). Relaxin has been found in males of various species, usually within the 
accessory se.\ glands such as the prostate and seminal vesicles (Sherwood, 1994, Juang et al., 
1996, Weiss. 1995). More commonly, however, relaxin is studied in females. The most 
common site ot production in females is the CL; however, in some species relaxin is found 
predominantly in the placenta or the endometrium. 
Rats and pigs are the most commonly studied species because their levels of relaxin 
are easilv detected in the CL as well as in the circulation during gestation. Relaxin 
accumulates in electron dense granules in the CL during the latter half of pregnancy 
(Anderson et al.. 19~"\i. .-\nderson et al.. 1973b, Belt et al.. 1971). Both species have 
moderate to low levels ot relaxin circulating until the antepartum period. At this time the 
relaxin containing granules in the CL are quickly reduced in number (Anderson et al., 
1973a; Anderson el al.,1973b) and there is a peak in the amount of relaxin found in the 
circulation (Felder et al.. 1986, Sherwood et al.. 1980). Following parturition, and during 
the estrous c\ cle, relaxin is not detectable in the circulation, and is minutely detectable in 
the CL. 
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Relaxin is involved in rescrucruring the collagen in the pelvic ligaments, as well as 
the cervix, to accommodate parturition. In 1926. Hisaw published a paper indicating that 
serum from pregnant guinea pigs resulted in a noticeable widenmg of the pubic symphysis 
when administered shorilv after estrus to virgin guinea pigs (Hisaw, 1926); the active 
faaor in the serum was later identified as relaxin (Fevold et al., 1930) and named for its 
relaxative characteristics. In addition to the changes seen in the cervix and pelvic hgaments, 
relaxin also plavs a role in the growth ot the mammary glands and nipples. 
Relaxin not onlv alters the histologic structure of tissues, but also has a physiologic 
action. It has a quiescent effect on the uterus during gestation. In animals treated with a 
monoclonal antibody to relaxin, the beginning ot parturition is delayed, it lasts much 
longer, and there is a higher percentage ot fetal death (Lao Guico-Lamm and Sherwood, 
1988). 
Relaxin has been stuciied in this reproductive context since the mid 1920's. It was 
not until nearU sixt\ vear:> later thai relaxin was also found to play a role at the level of 
the brain. Since that time the rat has been used as a model to show that: 1) there are 
relaxin binding sites in man\' discrete regions of the brain (Osheroff and Phillips, 1991); 2) 
preprorelaxin mRNA is present in regions of the brain in addition to those in which it has 
binding sites (Osheroff and Ho, 1993); 3) relaxin can elicit, as well as inhibit, the release 
of oxytocin and \ asopressin (.-W'P) from the neurohypophysis (Dayanithi et al., 1987; 
Summerlee et al.. 1984, Jones and Summerlee. 1986). 
Although much is known about relaxin's target tissues, its receptor has yet to be 
characterized. Numerous autoradiographic binding studies have been carried out that 
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demonstrate binding ot "P-Libeled relaxin in its target tissues (Sherwood, 1994). Studies in 
the mid 198C's, implicating reiaxm's role in the brain, led to the discovery of relaxin 
binding sues in the rat brain (Osherolf et al., 199C). A subsequent study by Osheroff and 
Phillips (1991) detailed the exact location ot binding sites in the male and female rat brain. 
Areas where relaxin binding was seen include the: subfornical organ (SFO), organum 
vasculosum ot the lamina terminalis (OVLT), the PVN and SON of the hypothalamus, as 
well as the neocortex, hippocampus, thalamus, amygdala, midbrain and medulla. 
Particular interest was given to the binding sites in the PVN and SON because previous 
data had implicated relaxin in the control of OT and AVP release, both of which are made 
in these nuclei. Binding sices in the SFO and 0\'LT were also considered significant 
because ot their incomplete blood brain barrier and therefore potential action as mediators 
of relaxin's eftects on the release ot OT and AV'P trom the supraoptic and paraventricular 
nuclei. 
The SFO IS a circumventncuLir organ, which bv definition means that it is exposed 
to the ventricles, and thereb\ is aUo exposed to the cerebral spinal tluid (CSF). 
Histologically, man\ ot the capillaries u ithin the SFO are fenestrated (Dellmann and 
Simpson, 1979), which allows substances trom the blood to pass into the tissue and vice 
versa. This incomplete blood brain barrier is also tound in other circumventricuiar sites, 
such as the OVl.T .md the area postrema (W'eindel and Sofroniew, 1981). 
Circumventricuiar organs maintain an intact blood-CSF barrier, which prevents 
substances (which have passed trom the blood into the brain through fenestrations in the 
capillaries) trom passivelv dittusing into the cerebral spinal fluid. This is accomplished 
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through tight junctions bet^veen the ependymal cells lining the ventricular surface of the 
SFO. Circulating peptides can. however, selectively pass from the blood into the CSF 
through circumventricular sues (Pardridge et al., 1981). The SFO sends efferents to both 
the SON and PVN. as well as to areas in the anteroventral third ventricular area of the 
preoptic region (Miselis, 1981). Summerlee et al. (1987), have shown that lesions of the 
SFO completelv block the inhibitory effects that relaxin has on the reflex milk ejection. 
This information, along with that demonstratmg the location of relaxin bmding sites in 
the SON and P\'N, suggests two possible routes tor the action of relaxin on the release of 
OT and A VP; 1) relaxin is selectively transported from the circulation into the CSF 
through the SFO. and trom there reaches its bindmg sites in the SON and PVN or 2) 
relaxin is selectivelv transported trom the circulation into the SFO, and is then 
transported trom the SFO lu the SON and PVN along the efferent projections from the 
SFO. 
Because reLi.xin spcciticallv attects magnocellular neurons of the SON and PVN, 
and no information is available concerning the selective transport of relaxin into the CSF, 
researchers have decided to look tor relaxin niRNA within the brain ot rats (Gunnersen et 
al., 1985; Osherolt .uul I lo. 1993). Both groups demonstrated a ikb transcript in rat brain 
using Northern blots, and Gunnersen and colleagues also found this transcript in uterus, 
prostate gland, pancreas and kidney. The weight ot this isolate correlates well with that of 
preprorelaxin. Osheroff and Ho (1993) then went on to localize relaxin mRNA to several 
distinct regions within the brain: the anterior olfactory nucleus, tenia tecta, pyriform-
and neo-cortices. and area> 1-^ and ihe dentate gyrus of the hippocampus. No 
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conclusions were drawn bv the authors as to the significance of these sites. Relaxin has a 
low-moderate concentration ot binding sites in all of these regions with the exception of 
the tenia tecta and the piriform cortex, where no binding sites exist. In addition to the 
mRNA studies, Gunnersen et al. (1995) also found the relaxin protein, using 
immunohistochemistrv. in the arcuate nucleus ot the rat brain. Relaxin has also been 
identified immunohistochemically in the neurohypophysis of the pig (Bagnell, 1990). 
Relaxin has also been discovered in the CSF. Following administration of relaxin 
into the svstemic circulation ot rats, relaxin was detected in the CSF from 1-20 minutes 
post injection (Parr\' ct al.. 1991). Interestinglv, when anti-relaxin is administered 
intracerebroventricularK . the length ot gestation is shortened as well as the duration of the 
onset of straining prior to expulsion (Summerlee et al., 1998). This indicates that 
endogenous rela.xin found in the CSF, either trom the preprorelaxin mRNA in the brain 
or through its abilit\ to enter the CSF trom the svstemic circulation, is important in the 
timing ot birth. 
Numerous studies have been published regarding the effect that relaxin has on 
AVP, blood pressure and heart rate. Intravenous (i,v.)and i.e.v. relaxin administered to 
rats has been shown to incre.ise circulating .A\'P as well as to raise blood pressure 
(Mumford et al.. 1989: Parr\- et al., 199C; "l ang et al., 1995). Relaxin's effects on the heart 
are mediated partly b\' the central release ot .-WP, but also by direct interaction with the 
heart (Kakouris el al.. 1992), Rcla.\ui has binding sites in the atria (Osheroff and Ho, 
1993), It has been shown ifi vara to be a very potent inotrope and chronotrope (Kakouris 
et al,, 1992), although, at low doses ii decreases heart rate (Yang, et al., 1995). Relaxin's 
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central actions on the release ot AV'P seem to be mediated by the SFO and angiotensin II. 
Lesions ot the SFO (Nlumtord et al. 1989) and i.e.v. administration of angiotensin II 
antagonists both (Parrv and Summerlee, 1991) block the pressor effects of relaxin, and 
angiotensin 11 antagonists also decrease circulating levels of vasopressin (Geddes et al., 
1994). 
The relationship between OT and rela.\;in has been studied in rats and pigs both in 
vitro and m vrjo. .\n in viiru stud\' on the rat neurohypophysis by Dayanithi et al. (1987) 
showed that under basal conditions, rela.xin inhibits the release of oxytocin; however, 
when the nerve endings were depolarized, oxvtocin secretion was potentiated. In vivo 
studies in rats have shown contradictorv results. In 1984, Summerlee and colleagues found 
that I.v. and i.e.v. administration ot relaxin in rats had an inhibitory effect on the reflex 
milk election, which is mediated through the release ot oxytocin. In contrast. Way and 
Leng (1992) shou ed that OT lev els are elewued tollowing i.v. administration of relaxin to 
ovariectomized rats. The\- also demonstrated that the firing rate of OTergic neurons in the 
SON is increased tollow ing i.v. relaxin administration. They hypothesized that the 
contradiction between these iwo studies was due to a discrepancy in interpretation. In 
addition to the atorementioned tindings, W'av and Leng (1992), in agreement with 
Summerlee et al.fl984), also reported that i.v. relaxin inhibited the reflex milk ejection. 
Reflex milk ejectiiMis. however, are due to brief episodes of synchronized high-frequency 
discharges of OTergic cells, which are the consequence ot the activation of spinal afferents 
from the nipples. These bursts, therefore, are not due to pharmacological (or 
physiological) activation ot OTergic cells. Therefore, inhibition of the milk-ejection 
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pathway and activation ot OTergic cells are independent consequences of relaxin 
administration. Summerlee s research group (Geddes et al., 1994; Parry et al., 1994) went 
on to contirm the results ot \X'a\' and Leng (1992) and. in addition, reported that relaxin's 
effect to increase the release of OT and AVP was attenuated in late pregnancy m the rat. 
InterestingK". a stud\- in goats (Peaker et ai., 1995) showed that the responsiveness of the 
myoepithelial cells to oxytocin is varvingly dependent upon intramammary relaxin. 
Relaxm decreases the mammarv glands sensitivity to oxytocin during pregnancy and 
immediatelv tollowmg parturition, but not during the remainder of lactation. 
A study in rats showed that the i.e.v. administration of relaxin (McKinley et al., 
1997), increases the expression ot Fos in OTergic cells of the hypothalamus. Fos is the 
protein product ot an ininiediate earl\ gene called c-/oi. which is activated by numerous 
proteins, one ot which is relaxin. Fos acts as a transcription factor by binding to the AP-1 
site on genes to alter their transcriptujn. It binds as a heterodimer with Jun, the protem 
product of another immediate early gene, and can either suppress or enhance the 
transcription ot the gene to which it binds. The expression of Fos in OTergic cells 
following the administration ot relaxin suggests that relaxin is acting to change the 
transcriptional activitv within those cells. 
Research has also been conducted in pigs on the relationship between oxytocin and 
relaxin. In vitro studies on sow neurohypophyses showed that relaxin has no effect on the 
release of oxvtocin (Porter et al.. 1992). The same study indicated that relaxin does not 
alter the circulating concentration ot C^T when administered to lactating sows. The effect 
of relaxin on circulating 01 in pregnaiu pigs li being investigated. 
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In summarv, OT and relaxin are hormones involved during pregnancy and 
parturition. Oxvtocin binds to receptors in the myometrium at term, to cause uterine 
contractions, resukmg m tecal expulsion. Rcla.xm has a quiescent effect on the 
myometrium prior to term, and appears to prevent the premature release of OT during 
the antepartum period. The present dissertation further explores the relationship of the 
two hormones in pregnant rats and pregnant pigs. 
Dissertation organization 
The present dissertation consists of three papers, comprising Chapters 2-4. The 
paper found in Chapter 2 has been submitted to Biology of Reproduction for publication; 
the paper found in Chapter 3 has been published in Neuroendocrinology (1997); and the 
paper in Chapter 4 will be submitted to Neuroendocrinology for publication. The papers 
were preceded b\ a general iniroducuon and are followed by a composite summary and 
general discussion. The literature cued in the introductory and conclusionary chapters is 
referenced following the general discussion. .\11 ot the animal and laboratory work found 
within this paper was carried out bv the author in the laboratorv of Carol D. Jacobson, 
and, with Karen Langner's help on the radioimmunoassays described in Chapter 2 in the 
laboratorv ot Llo\ d L. .\nder-,un. 
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CHAPTER 2 
EFFECT OF CIRCULATING RELAXIN ON OXYTOCIN AND PROLACTIN 
CONCENTRATIONS DURING PREGNANCY IN THE GILT 
A paper submitted to Biology of Reproduction 
Patricia A Heine, Carol D Jacobson, Ted B Bailey, John Klindt, Lloyd L Anderson 
ABSTRACT 
In gilts, circulating concentrations of relaxin reach an antepartum peak within 2 d 
of parturition. During this time, many endocrine changes are occurring in preparation for 
birth. The present study was designed to determine the effect of intravenously 
administered relaxin on the circulating concentrations of oxytocin and prolactin in 
pregnant gilts. Six midgestational and eight late gestational gilts were utilized in this study. 
Gilts from each gestational period were assigned to one of two treatment groups: relaxin 
or isotonic saline. Gilts received one of the two treatments and were subsequently bled at 
sequential time points for a 3-h duration. Prior to treatment, late gestational gilts were 
ovariectomized to remove the primary source of endogenous relaxin (followed by 
progesterone administration to maintain pregnancy). Acute exposure to relaxin had no 
significant effect on the circulating levels of either prolactin or oxytocin at the late 
gestational age. In mid gestational gilts, however, a significant difference was noted in the 
circulating concentrations of oxytocin. In the late gestational group, removal of 
endogenous relaxin did unexpectedly result in a substantial transient increase in the 
circulating levels of oxytocin and a lesser, yet significant increase in the circulating levels of 
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prolactin. These results indicate that intravenously administered relaxin is capable of 
increasing the circulating concentration of oxytocin during midgestation, and suggests that 
removal of endogenous relaxin causes a release of oxytocin into the circulation during late 
gestation. 
INTRODUCTION 
Pregnancy, especially near term, is a time when the hormonal milieu is 
considerably altered from its normal state. Present in the circulation during pregnancy are 
hormones that are not detectable in the non-pregnant state, as well as altered levels of 
hormones regularly found in the circulation. The source of these hormones can be tissues 
that are present only during pregnancy (placenta) or other endocrine tissues such as the 
ovaries or pituitary gland. How these hormones interact and the result of their 
mteractions is of ongoing interest. 
Gestational length in pigs is 114 d. Many studies have been performed measuring 
the levels of various hormones throughout pregnancy and during parturition in pigs [1-3]. 
One hormone of particular interest, relaxin, is made in the corpora lutea (CL) and is 
therefore detectable in the circulation primarily during pregnancy. Prolactin (PRL) has 
been shown in recent studies to be released in gilts in response to intracerebroventricularly 
delivered relaxin[4]. In vitro studies suggest that relaxin increases the release of PRL [5, 6]; 
however, because oxytocin (OT) is a putative releaser of PRL [7], it is plausible that OT is 
mediating the release of PRL in response to relaxin. It has been shown in rats that OT and 
vasopression (VP) are released following injection with relaxin [8, 9]. A study utilizing 
lactating pigs, however, demonstrated that i.v. administration of relaxin had no effect on 
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circulating OT concentrations [10]. But, because relaxin is not found in the circulation 
during lactation, this experimental design did not test a physiologically normal hormonal 
interaction. The present study utilized late and midgestational gilts to elucidate the effects 
of relaxin on OT and PRL during a time when gilts are normally exposed to their own 
circulating relaxin. 
We previously determined that levels of PRL and relaxin are equivalent in 
Yorkshire and Meishan gilts during late pregnancy [11]. The primary objective of this 
study was to determine if intravenously administered relaxin affected the circulating levels 
of OT and PRL in pigs during mid- and late gestation. The secondary objective was to 
determine basal blood concentrations of these hormones in midgestation in the presence of 
relaxin and in late gestation in the absence of relaxin. 
Material and Methods 
Animals 
All pigs were housed at the Iowa State University Animal Reproduction Farm. 
They were fed a corn- and soybean meal diet once per day and had free access to water. 
The room in which they were housed had a controlled ambient temperature of 23-25 ° C. 
All procedures were approved by the Iowa State University Committee on Animal Care. 
Six Meishan and eight Yorkshire gilts, weighing approximately 115-180 kg were 
bred naturally and housed in group pens until 2 d prior to surgery for jugular cannula 
placement as well as ovariectomy (OVX) in late gestation. At this time, gilts were moved 
to individual pens, where they were housed for the duration of the study. 
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Treatments 
Following breeding, gilts were placed into groups based on breeding date and blood 
line. Animals within each group were randomly assigned to receive either relaxin or 
isotonic saline. To determine the baseline hormone levels, gilts in midgestation (beginning 
on gestational day 44; g44) were bled every 12 h for 5 d prior to treatment. On the day of 
treatment, either relaxin or saline was administered intravenously to each gilt according to 
her group placement (see the Blood Sampling section). Gilts in late gestation underwent 
surgery between gl05 and gl07. At that time a jugular cannula was placed and ovaries were 
removed. From the time of surgery until the end of the experiment, gilts received 200 mg 
(50 mg/45 kg body weight) of intramuscular progesterone (dissolved in 10 ml sesame oil) 
every 12 h to maintain pregnancy. Relaxin or saline was administered on gl09-glll. Blood 
was sampled in the same manner as it was in the midgestational gilts. 
Surgery 
Anesthetic induction of gilts was achieved by intramuscular injection of ketamine 
(10 mg/kg). Anesthesia was then maintained with halothane, delivered through a mask 
connected to a semiclosed circle anesthetic machine (Ohio Medical Products, Madison, 
WI). Oxygen levels were set at 2 1 of oxygen/min with delivery of 1.5-2% halothane. 
A cannula (i.d.,1.27 mm; o.d., 2.29 mm; Tygon® microbore tubing, Fisher 
Scientific, Pittsburgh, PA) was placed in the external jugular vein and passed caudally to 
the level of the right atrium. At the point of entry through the skin of the neck, the 
cannula was secured to the surrounding tissues using silk suture. The free end of the tubing 
was tunneled under the skin and exteriorized at the nape of the neck and secured to the 
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skin using prolene (#1; Ethicon, Somersville, NJ). The cannula was filled with heparinized 
saline (15units/ml) to maintain patency. 
In addition to cannula placement, late gestational gilts underwent ovariectomy 
(OVX). Both procedures were conducted during the same anesthetic episode to reduce the 
chance of fetal complications due to multiple anesthetic exposures. Ovariectomy was 
performed through a midventral laparotomy. To enter the peritoneal cavity, a 20-cm 
incision was made on the ventral midline extending from the level of the second-from-the-
last teat, cranially. Ovaries were elevated from the abdomen, and the proper ligament 
between the ovary and uterus and the mesovarium were crushed. Chromic cat gut (#3; 
Braun, Jorgensen Laboratories, Inc., Loveland, CO) was used to ligate (by transfixation) 
the ovarian pedicle allowing for excision. The remaining ovarian stump then was 
cauterized. Penicillin G (Solvay, Mendota Heights, MN) was administered 
intraperitoneally as well as intramuscularly (7 million lU). The abdominal incision was 
closed in three layers. Chromic cat gut (#3; Braun) was used to close the two deep layers, 
utilizing a vest-over-pants pattern on the dorsal rectus sheath and a simple continuous 
pattern on the fat layer. A Ford interlocking pattern utilizing 1/8" cotton umbilical tape 
(Ethicon) was used to close the skin. Following surgery, the gilts inhaled 100% oxygen 
until they regained consciousness and were then wheeled back into their individual pens 
with heated floors for full recovery. 
Blood Sampling 
The blood sampling protocol was the same for mid- and late gestational gilts. One 
10-ml blood sample was obtained every 12 h from each gilt's i.v. cannula. To maintain 
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patency, cannulas were flushed with heparinized saline following blood withdrawal. The 
collected blood samples were transferred to heparinized vacutainer tubes (Becton 
Dickenson, Rutherford, NJ) and centrifuged for the recovery of plasma, which was stored 
in duplicate in plastic tubes. One tube contained 20 |J,1 protinin A (ICN Pharmaceuticals, 
Inc., Costa Mesa, CA) to prevent the proteolysis of small peptides such as oxytocin. Tubes 
were snap frozen at -70 ° C and then stored at -20 ° C until radioimmunoassays (RIAs) 
were run for relaxin, OT, PRL, and progesterone. All four hormones were assayed in both 
gestational ages. Relaxin was assayed to determine baseline levels in the midgestational gilts 
and to affirm that the treatment did enter the circulation, and reached levels similar to 
those seen after degranulation from the CL in late pregnancy. Progesterone was assayed to 
determine baseline values in the midgestational gilts and to verify that an adequate level of 
the hormone was being exogenously maintained in the late gestational group. 
Days on which the gilts received their treatments, blood samples were drawn 20 
and 10 min prior to treatment administration. Treatments were given through the same 
cannula from which samples were drawn. At time zero, gilts received either 1 mg [12] 
purified porcine relaxin (C. Schwabe, Medical University of South Carolina, Charleston, 
SC) dissolved in 2 ml of isotonic saline, or just the vehicle. Blood samples then were 
obtained at 2.5, 5, 10, 15, and 20 min following the challenge, and every 20 min thereafter 
for a total of 180 min. The procedure for blood sample collection was the same as 
previously discussed. 
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Radioimmuonassay of progesterone, relaxin, prolactin and oxytocin 
Plasma progesterone was extracted with a benzene-hexane mixture (1:2 vol/vol) 
using a modified version of the procedures described by Louis et al.[13]. One hundred 
microHters of plasma samples were extracted in duplicate. A third 100-|il replicate received 
5,000 cpm [l,2,6,7-N-^H]progesterone (97 Ci/mmol; NEN Research Products, Boston, 
MA). With modification of the RIA procedure described by Anderson et al.[14], plasma 
extracts were assayed for progesterone using the fully characterized antibody (GDN 
antiprogesterone-ll-BSA 337;[15, 16]). The limit of detection of the progesterone assay was 
230 pg/tube. The average intraassay coefficient of variation (CV) was 6.85% and the 
interassay CV was 4.03%. The mean recovery of P4 after benzene-hexane extraction was 
90.0%. 
Relaxin levels in the plasma were quantified in duplicate in aliquots of 100 |il. 
Monotyrosylated relaxin, prepared by C. Schwabe, was radioiodinated by the chloramine 
T method, and served as the tracer. The primary antibody, R6, was provided by B.C. 
Steinetz (New York University Medical Center, Tuxedo, NY), and the secondary 
antibody was goat anti-rabbit y-globulin. The procedures were followed as have been 
previously described [17, 18]. The assay sensitivity was 40 pg/tube. The average intra- and 
interassay CVs were 3.85% and 7.3%, respectively. 
Prolactin plasma concentrations were quantitated using a double-antibody RIA 
[19], Prolactin (USDA-pPRL-I-1) was radioiodinated by the chloramine -T method to a 
specific activity of approximately 90 |j.ci/|j.g. Primary antibody was purchased from 
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Research Products International Corp. (Mt. Prospect, IL, Lot 10115), and 100 |j.l at a 
dilution of 1:37,500 was added to each tube. Reference preparation was USDA-pPRL-B-1. 
Each tube contained 200 (il of plasma. The limit of detection was 0.15 ng/tube, intraassay 
CV was 13.1 ± 10.3% (mean ± SD), and interassay CV was 15.1 ± 7.6% (mean ± SD). 
Concentrations of oxytocin in the plasma were determined by use of a double 
antibody procedure and '"'I oxytocin (NEN Research Products) as the tracer. The primary 
antibody, made in rabbit, was a gift from J. Kotwica (Division of Reproductive 
Endocrinology and Pathophysiology, Center for Agrotech and Veterinary Science, Polish 
Academy of Sciences, Olsztyn, Poland). The secondary antibody was a goat anti-rabbit y-
globulin (Organnon Teknika, Cappel Research Products, Durham, NC). Plasma oxytocin 
was extracted using acetone (2 ml, cold)/ 0.5 ml duplicate. The extracts were resuspended 
in 0.4 ml of assay buffer. To this volume, 100 jj,l of 1:11,500 of the primary antibody was 
added and this was incubated at 4 ° C for 24 h. The tracer was then added at 
approximately 5,500 cpm/100 )il. This was incubated at 4 ° C for 24 h. Then 200 |al of the 
secondary antibody at 1:15 was added, and this was incubated at 4 ° C for 48 h. Then 200 
|j.l of polyethylene glycol (Sigma, St. Louis, MO) and 3 ml of 0.01 M phosphate buffered 
saline were added, and this was centrifuged for 1 h at 3,000 x g. The supernatant was 
decanted and the pellets were counted in the y spectrometer for 1 min. The sensitivity of 
the assay was 0.97 pg/tube. The average intraassay CV was 3.7%, and the interassay CV 
was 8.1%. The mean recovery of OT after acetone extraaion was 75.5%. 
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Statistical Analyses 
The experimental units were the individual gilts. Analyses of midgestational and 
late gestational stages were completed independently. Because each gilt was measured 
several times our initial analysis was a univariate ANOVA corresponding to a split-plot 
design, with time as the split-plot factor [19], Treatment (saline or relaxin) means were 
compared via the ANOVA F-test. Tests for time and time by treatment interaction effects 
were completed using reduced numerator and denominator degrees of freedom to account 
for the correlation of measurements at the different times. Finally, tests for linear and non­
linear trends over time were carried out for the relaxin treatment [20]. All tests were 
conducted using a five percent-level of significance. 
RESULTS 
Midgestational Gilts 
Baseline 
Baseline hormonal values for gilts in midgestation are shown in Fig. I. 
Midgestational values for all four hormones are similar to those measured previously [3, 
11]. Circulating concentrations of OT, which previously had not been documented during 
midgestation, averaged 3 pg/ml of plasma. 
Following treatment 
After receiving exogenous relaxin, the detected levels of circulating relaxin were 
similar to those previously determined during the antepartum peak [3, 22]. Following 
relaxin administration, the circulating PRL concentration gradually increased over the 3-h 
trial (Fig. 2A), however, the linear component of the line graph (Fig. 2A) was not 
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significantly different from a line with zero slope. Plasma OT levels in the midgestational 
gilts underwent a transient rise followed by a rapid return to baseline (Fig. 2B). The linear 
component of the relaxin treatment group in Fig. 2B indicates a significant difference from 
a line of zero slope (p < 0.002). As was expected, circulating progesterone showed no 
response to the administration of relaxin (Fig. 2C). 
Late Gestational Gilts 
Baseline 
Ovariectomy affects circulating progesterone and relaxin concentrations because 
the CL are the main source for both hormones. Therefore, following removal of the 
ovaries, there should be no detectable relaxin or progesterone in the circulation. As was 
expected, the concentration of plasma relaxin (Fig. 3D) was not measurable in gilts post-
OVX. But, P4 was detectable due to its exogenous replacement. Progesterone values 
plateaued at 4 d post-OVX (Fig. 3C). Sufficient circulating P4 was present in all gilts, 
validated by the lack of spontaneous abortions, and also the comparative data from intact 
gilts. The circulating concentrations of PRL and OT both decreased significantly in the 
first 2 d following ovariectomy (Fig. 2A and 2B). The OT concentration in the circulation 
reached an average of 12 pg/ml immediately following OVX, and by 3 d post-OVX had 
plummeted to 2.5 pg/ml, where it remained for the duration of the study. A regression 
analysis showed that the linear component of this line was significantly different from a 
line of zero slope (p > 0.0001). Plasma PRL levels were 3.5 ng/ml following OVX, and by 
3 days post-OVX had decreased to 1.5 ng/ml, where they remained throughout the 
duration of the experiment. Regression analysis of the linear component of this line 
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showed a significant difference from a line a zero slope (p > 0.0002). Data from intact gilts 
at similar gestational points are shown for comparison. 
Following hormone or vehicle treatment 
Following administration of exogenous relaxin, detectable levels of relaxin m the 
circulation were similar to that seen in the antepartum peak [3, 22].The response of 
circulating OT and PRL concentrations to i.v. administration of relaxin was insignificant 
in the late gestational gilts. Plasma PRL incurred only a transient rise (Fig. 4A), which did 
not occur until 20 min after relaxin had been administered and slowly returned to baseline 
values over the remainder of the study. The circulating concentrations of OT did not 
show any response to i.v. relaxin administration in the late gestational group (Fig. 4B). 
DISCUSSION 
The intravenous administration of relaxin results in a significant increase in the 
circulating concentration of OT in midgestational gilts. Surprisingly, changes were noted 
in the circulating concentrations of OT and PRL in response to removal of the ovaries in 
late gestation. Because progesterone was replaced, the changes seen likely resulted from the 
acute drop in circulating relaxin concentrations. This unexpected change is similar to one 
documented in late pregnant rats, in which ovariectomy decreased the endogenous opioid 
inhibition of OT release [23]. 
Midgestational gilts 
The nonstatistically significant increase in circulating PRL following treatment 
with relaxin may be explained by similar findings seen in a previous study [4], in which 
relaxin was administered intracerebroventricularly to pseudopregnant gilts. This caused a 
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rapid transient rise in peripheral prolactin. The increases in circulating PRL are much less 
pronounced in the present study; however, it can be assumed that relaxin administered 
intravenously reached the adenohypophysis in smaller amounts than it did using the 
intracerebroventricular method of administration. 
The significance of the increase in circulating OT in the midgestational gilts 
suggests that relaxin's effect on the release of OT in pigs is similar to that in rats [8]. In the 
current study, the increase in circulating OT, in response to relaxin, peaks at 30 min 
following relaxin administration and has returned to baseline by 60 min post treatment. 
The rise in PRL doesn't begin until 60 min post treatment and peaks at 100 min, followed 
by a return toward baseline. Circulating OT, a putative releaser of PRL, may be 
responsible for this late increase in PRL, however, the half life of OT in the circulation is 
only 3 min, which would indicate that the cellular mechanism behind the OT induced 
release of PRL must be slow. From another point of view, although the increase in 
circulating OT was significant following the administration of relaxin, the absolute values 
of the OT in the circulation are still within the limits of the baseline values (Fig. IB). This 
suggests that the changes seen may only be variations within the normal range of 
circulating oxytocin. 
Late gestational gilts 
The loss of relaxin as seen in the present study results in a response of the 
circulating concentrations of both PRL and oxytocin. The circulating levels of PRL 
immediately following OVX are greater than baseline values; however, there is a rapid 
return to the baseline values. This reduction in circulating PRL could be a direct or 
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indirect result of the loss of relaxin. Prolactin has been shown to respond to changes in 
relaxin [4-6], but it also appears to be regulated by oxytocin[7]. Oxytocin's diurnal rhythm 
mirrors that of PRJL [24], suggesting that fluctuations in OT release result in changes in 
peripheral PRL concentrations. It is likely that the marked decrease in circulating PRL 
following the loss of relaxin was due to prolactin's response to the decrease in oxytocin. 
Following the removal of relaxin, the circulating concentration of PRL is much 
lower than that seen in the intact gilts. This suggests that the presence of relaxin may be 
necessary for the release of PRL. In support of this, previous work has shown that relaxin 
has a much more potent effect in females on the release of PRL from cultured cells of the 
adenohypophysis than it does in males [6]. 
General discussion 
The physiology of the hormonal milieu during the antepartum period in swine is 
such that relaxin peaks within 24 h of parturition. Oxytocin does not increase in the 
circulation until after parturition begins [25]. Therefore, prepartum circulating relaxin 
may prevent a premature release of oxytocin. Oxytocin is produced in the supraoptic and 
paraventricular nuclei of the hypothalamus and is released into the circulation from the 
neurohypophysis. In the rat, relaxin, which has been shown in the cerebral spinal fluid 
[26], binds to the supraoptic and paraventricular nuclei [27], making it feasible that relaxin 
alters some facet of OT production [28]. Additionally, relaxin is found in the 
neurohypophysis of the pig [29], indicating that relaxin may play a role in monitoring the 
release of OT into the circulation. In vitro studies have shown that relaxin does increase 
the release of OT from rat neurohypophysis [30]. 
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Studies on the effect of relaxin administration on plasma OT levels have had 
contradictory results. Results from early studies on rats indicated that relaxin inhibited the 
release of oxytocin [31]. Contrary to these results, further studies indicated that in the rat, 
OT is released into circulation following the administration of relaxin [8], The current 
study indicates that in gilts, a loss of relaxin in late gestation results in the release of 
oxytocin. The circulating concentrations of OT are elevated above the baseline values 
immediately following OVX and then rapidly decline to levels at or below baseline. 
Likewise, a study in rats indicated that removal of relaxin decreased the inhibitory effect of 
opioids on the release of oxytocin during late pregnancy [23]. This is likely the same 
mechanism that was seen in the current study. The opioid dynorphin is co-released with 
VP from the neurohypophysis and binds locally to kappa opioid receptors inhibiting the 
release of oxytocin [32]. 
Why does circulating OT in the late gestational group show no response to 
treatment with relaxin? A previous study [10] indicated that relaxin had no affect on 
circulating OT in lactating pigs. This would indicate that after parturition and during 
lactation, oxytocinergic neurons are unable to respond to relaxin. Normally, pigs are 
exposed to an antepartum peak followed by a rapid decrease in circulating relaxin 
concentrations [2, 3]. Oxytocin is then seen to increase after an hour or more of active 
labor [25]. In the current study, the loss of circulating relaxin post-OVX may activate the 
same hormonal response as is seen in the antepartum relaxin decrease. The large release of 
OT following OVX could be one of the normal hormonal responses to a loss in 
circulating relaxin. Interestingly, the effect of opioids on OT is only seen during 
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pregnancy. Therefore, during other reproductive stages, relaxin would be unable to 
interact with the opioids to alter the release of oxytocin. This may explain why, in the 
current study, there was no change in circulating OT following an acute dose of relaxin in 
the ovariectomized late pregnant gilts, nor was there a response of lactating gilts to relaxin 
in the previous study [10]. 
Physiologically, the relationship between relaxin, PRL, and OT appears to be 
complex. From previous studies it is clear that there is an interrelationship between the 
three hormones. During late pregnancy, prolactin is luteotropic in the pig [33], suggesting 
that the increase in circulating relaxin during pregnancy may act to release PRL for this 
purpose. Relaxin in the rat acts to release OT, which can then enhance the release of 
prolactin. This experiment shows that relaxin is also responsible for increasing the release 
of OT in midgestational pigs. In addition, findings herein support results from work 
previously completed in the rat and implicate relaxin as a control mechanism preventing 
the premature release of OT in the late pregnant pig. 
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Figure 1. Midgestationai baseline hormonal values of prolactin (A), oxytocin (B), 
progesterone (C) and relaxin (D). Gilts were bled every 12 h for 5 d beginning on 
Values are the mean ± SE (n = 6). 
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Figure 2. Midgestational hormonal values for gilts treated with relaxin (closed shapes; n = 3) 
or saline (open shapes; n = 3). Treatment (2 ml saline with or without 1 mg dissolved relaxin) 
was administered intravenously at time zero. Blood was drawn prior to treatment 
administration, as well as over a 180 min period following treatment. Hormone profiles are 
present for prolactin (A), oxytocin (B), progesterone (C) and relaxin (D). Data points are the 
mean ± SE. 
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Figure 3. Gilts were ovariectomized at the beginning of the study, and were bled to obtain 
baseline hormonal values for 8 d following surgery (designated as day 0). Pregnancy was 
maintained using IM progesterone b.i.d. Hormone profiles are shown for prolactin (A), 
oxytocin (B). progesterone (C) and relaxin (D). Data from intact gilts at the same gestational 
time points is included for comparison (comparative data is not shown for the oxytocin 
values). Data points are the means ± SE (n = 8). 
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Figure 4. Late gestational gilts were treated with eitiier relaxin (closed shapes; n = 4) or 
saline (open shapes; n = 4) following ovariectomy. Treatments (2 ml saline with or without 1 
mg dissolved relaxin) were administered at time zero. Blood was drawn prior to treatment 
and for a period of 180 min following treatment. Hormone profiles are shown for prolactin 
(A), oxytocin (B) and relaxin (C). Data points are the mean ± SE. 
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CHAPTERS 
RELAXIN-INDUCED EXPRESSION OF FOS IN THE FOREBRAIN OF THE 
LATE PREGNANT RAT 
A paper published in Neuroendocrinology 
Patricia A Heine, Shi Di, Lynne R Ross, Lloyd L Anderson, 
Carol D Jacobson 
ABSTRACT 
Relaxin, administered parenterally, has been shown to increase the release of 
oxytocin (OT) into the circulation and increase the firing rate of OTergic neurons. The 
objective of the present study was to determine if relaxin administration can result in the 
expression of a transcription factor, which would suggest that it alters transcriptional 
activity within OTergic neurons at the level of the hypothalamus. Primigravid rats were 
ovariectomized and a jugular cannula was inserted on day 11 of gestation (gll). Pregnancy 
was maintained by implanting 17b-estradiol and progesterone caplets subcutaneously at the 
time of ovariectomy. At gl9, rats were challenged with intravenous relaxin or isotonic 
saline and the brains were removed for study. Immunohistochemistry was performed on 
coronal brain sections, utilizing Fos as a marker of cellular aaivation. In the group receiving 
relaxin, Fos-like immunoreactivity (Fos-IR) was abundant only in the supraoptic (SON) and 
paraventricular nuclei (PVN) of the hypothalamus, as well as in the subfornical organ 
(SFO). In contrast, Fos-ER in the group given isotonic saline was lacking in these three brain 
regions. A double label study using antibodies against Fos and OT, demonstrated that a 
majority of the Fos labeled cells in the hypothalamus were OTergic. Because Fos can act as 
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a transcription faaor, we interpret these data to indicate that transcription within OTergic 
cells is altered following relaxin administration, with abundant Fos-ER being limited to the 
SON and PVN of the hypothalamus and the SFO during late pregnancy in the rat. 
INTRODUCTION 
Relaxin is a polypeptide hormone found in elevated concentrations during 
pregnancy, in a variety of vertebrates [1]. It is involved in many of the anatomical changes 
seen during the gestation of the rat, in part through its remodeling of collagen. Changes are 
seen in the cervix [2,3], vagina [3], and mammary apparatus [4]. Relaxin weighs 6000 daltons 
and is a member of the family of insulin-like growth factors [1]. In female rats, relaxin is 
made in the corpora lutea, where it is found in elevated concentrations in the latter part of 
pregnancy [5,6]. Relaxin concentrations in the rat first become detectable in the blood on 
gestational day 10 (glO), and plateau between 40-70 ng/ml by gl4 [1,7]. Serum relaxin levels 
during the antepartum period rise in two phases. The first rise occurs 60 h prior to 
parturition and is maintained until the second phase occurs about 24 h prior to parturition 
[1]. At these times, levels reach between 80 and 200 ng of relaxin per milliliter of serum 
[17]. 
In addition to the changes seen in the collagen of the reproductive tract, relaxin also 
has an influence at the level of the central nervous system (CNS). Although a receptor for 
relaxin has not yet been charaaerized, relaxin binding sites have been localized 
autoradiographically in the rat brain [8]. Areas that bind the ^"P-labeled relaxin include the 
subfornical organ, paraventricular, arcuate and supraoptic nuclei, amygdala, hippocampus 
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and neocortex. In addition, relaxin has been found immunohistochemically in the arcuate 
nucleus of the rat brain [9], Because relaxin is a large molecule, and not likely to pass the 
blood brain barrier (BBB), these findings led to a search for relaxin messenger RNA in the 
rat brain. The relaxin message was found in the brain, as well as in other tissues such as the 
placenta, endometrium, and prostate [9,10]. In the brain, relaxin mRNA was located in the 
hippocampus, taenia tecta, anterior olfaaory nucleus, piriform cortex and neocortex [10]. 
Additionally, relaxin has access to the CNS through circumventricular organs (CVOs). One 
CVO, commonly implicated in water balance homeostasis, is the subfornical organ (SFO). 
The SFO, like other CVOs, does not have an intact BBB, and therefore, allows substances 
to pass from the circulation into the neural tissue [11]. Because of its location surrounded 
by the dorsal third ventricle, peptides can be transported into the cerebral spinal fluid (CSF) 
through tight junctions between ependymal cells lining the ventricular surface [12]. In 
support of this theory, relaxin has been deteaed in the CSF following intravenous (i.v.) 
administration to rats [13]. And, in addition, relaxin's effects on the reflex milk ejection and 
pressor response are abolished following lesioning of the subfornical organ [14,15]. 
It seems that relaxin can modulate the concentration of circulating hormones 
through its actions in the central nervous system. Oxytocin (OT) [16], vasopressin [17,18], 
and prolactin [19] plasma levels are changed following relaxin administration. Previous 
work has shown that relaxin administered intravenously to rats increased the firing rate of 
neurons in the supraoptic nucleus (SON) and also increased circulating concentrations of 
OT in the periphery [16]. But, no studies have yet demonstrated an alteration in the 
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transcriptional activity within hormone producing neurons of the hypothalamus as a result 
of relaxin administration. 
Q-fos is a proto-oncogene that is aaivated immediately following certain cellular 
stimuli but is only active transiently [20,21]. Fos, the protein translated by c-fos, has been 
widely used as a marker of cellular activation. After Fos has heterodimerized with Jun (the 
product of a similar immediate-early gene), and under certain conditions as a homodimer 
[21], it can act as a transcription factor by binding to the AP-1 site on DNA [22,23]. Stimuli, 
such as osmotic stress [24,25] and copulation [26], have been shown to activate c-fos in the 
rat hypothalamus. In addition, Fos is present in nuclei following administration of peptides 
such as interleukin lb [27] and angiotensin II [28]. A preliminary study in our laboratory 
indicated that the peptide relaxin is also capable of activating c-fos. Because relaxin has been 
shown to influence the release of OT, the present study has been designed to examine the 
possibility that relaxin also alters the transcriptional activity within OTergic nuclei. The 
aim of this experiment is to locate Fos immunohistochemically to indicate areas of cellular 
activation and possible transcriptional activity. Utilizing Fos to functionally map the 
hypothalamus in response to relaxin has allowed us to explore our hypothesis that: i.v. 
administration of relaxin alters the transcriptional activity within the nuclei of OTergic cells 
of late pregnant rats. 
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MATERIALS AND METHODS 
Animals 
Sprague-Dawley virgin female rats, 2 months of age, were obtained from Harlan 
Sprague-Dawley (Indianapolis, IN). Rats were housed in plastic cages at 23°C, on a 14.10 h 
light-dark cycle, with food (Teklad Rodent Diet: Harlan Sprague-Dawley) and water 
available ad libitum. The animals and procedures used were in accordance with the 
guidelines and approval of the Iowa State University Committee on Animal Care. 
Animal Preparation 
Eight virgin cycling rats were housed with males and checked daily by vaginal smear 
at 08:00 for the presence of sperm. Females were returned to individual housing units upon 
positive sperm checks. The day on which sperm were found was designated gl. Rats were 
ovariectomized (OVX) on gll, to remove the primary source of relaxin, and rats in the 
experimental group were then given relaxin on gl9, to mimic the first spike that is seen in 
intact animals. The pregnancies were maintained by subcutaneously placed timed-release 
pellets of progesterone and IZP-estradioI. 
On gll, rats were anesthetized with ether, bilaterally ovariectomized (OVX) and 
fitted with a jugular vein cannula [29]. Carmulas were made of Silastic tubing (0.020 in. ED, 
0.037 in. OD) and sheeting (Dow Corning, Midland, MI). Each cannula was filled with 
heparinized saline (10 units/ml) and flushed every 24-48 h until the animals were sacrificed. 
During surgery, timed-release progesterone (63 mg) and 17b-estradiol (4.2 m^ pellets 
(Innovative Research of America, Sarasota, PL) were placed subcutaneously, at the level of 
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the interscapular space, to maintain pregnancy. This method of steroid replacement has 
previously been shown to sustain blood levels of progesterone and estradiol [30,31], which 
have been shown necessary to maintain pregnancy [32]. Blood levels of these hormones 
were not checked in the present experiment to determine if optimal levels were maintained. 
An average of six fetuses were retained per dam using this method of steroid replacement 
(data not shown). This number of fetuses is lower than one might expect, suggesting that 
circulating progesterone might not have been present in optimal levels. But, at this time, a 
definitive explanation is not apparent. 
Tissue Preparation 
All animals remained in the colony until gl9. This point in gestation coincides with 
the initial antepartum rise in the circulating levels of relaxin in intact rats [1]. Relaxin was 
administered to rats in the experimental group on gl9, to mimic this natural peak. Rats in 
this group (n = 4) were given 10 |J.g of relaxin [16] dissolved in 0.2 ml of 0.9% sodium 
chloride solution (isotonic saline), and control animals (n=4) received an equivalent volume 
of vehicle (n = 4). All treatments were given intravenously. This dosage of relaxin and route 
of administration has been shown to increase circulating concentrations of OT in rats [16]. 
Relaxin for this experiment was extracted from the ovaries of pregnant pigs and purified 
according to procedures described previously [33]. Injections were given through the 
indwelling cannula at 12:00. Two hours postinjection, rats were deeply anesthetized with 
ether, and transcardially perfused with 500 ml isotonic saline, followed by 500 ml chilled 4% 
paraformaldehyde (PF; pH 7.3). Ail rats were checked for viable fetuses, and only those 
with at least four live fetuses were used in the study. The dams' brains were then removed 
and blocked using identifiable landmarks and postfixed in 4% PF for 24 h at room 
temperature. Brains were then sunk in a sodium phosphate buffered saline 30% sucrose 
solution at 4°C, followed by sectioning on a cryostat (Reichart-Jung 2800N) into 40 |im 
serial coronal sections. Sections were stored in tissue culture wells (one brain/six wells) 
containing cryoprotectant [34] at -20°C until processed for immunohistochemistry (IHC). 
Immunohistochemistry 
The protocol utilized for IHC was a modification of what we have previously 
reported [35,36] with some changes due to the nature of the tissue preparation. Free floating 
sections, 240-310 |j.m apart, were rinsed with 50 mM potassium phosphate buffered saline 
(KPBS). To rid sections of endogenous peroxidase, they were placed in 0.1% H2O2 for 20 
min at room temperature. Tissue was then incubated in blocking solution composed of 
KPBS, 1% bovine serum albumin (BSA; Sigma, St. Louis, MO), 0.4% Triton-X 100 (TrX; 
Sigma) and 1.5% Normal Goat Serum (NGS; Vector, Burlingame, CA), for 2 h. Tissue was 
subsequently incubated for 36 h at 4°C in rabbit polyclonal Fos antibody (Ab-2, Oncogene, 
Cambridge, MA) diluted to 1:1000 in KPBS, 1% BSA, 0.4% TrX and 1% NGS. Sections 
were then washed in KPBS with 0.02% Triton-X 100 (KPBS/TrX), followed by a 2-h 
incubation in biotinylated goat anti-rabbit secondary antibody (2°; Vector), composed of 
diluent: KPBS/TrX, 1% BSA, 1.5% NGS plus 0.5% 2° antibody. This same diluent was 
used to make the Avidin Biotin Complex (ABC; Vector Elite Kit), using 0.2% ABC. 
Sections were incubated in ABC for 1 h at room temperature. Following additional washes, 
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the tissue was reacted with diaminobenzidine (DAB; Sigma) in a solution consisting of 0.1 
M sodium acetate, 2.5% NiSO^, 0.04% DAB and 0.01% HjO,, for 8 min. The reaction was 
terminated with isotonic saline. The tissue sections were then mounted onto gelatin coated 
slides, dried overnight, counterstained using a 1% neutral red solution (Fisher Scientific, 
Pittsburgh, PA), dehydrated in graded alcohols and coverslipped. Negative controls, used in 
each run, were generated by omitting the incubation in primary antibody and substituting 
blocking solution during the incubation period. Double label study 
The double label IHC study was performed in the same manner as the single label 
study for the first 2 days. Following termination of the DAB reaction, the tissue was washed 
four times in KPBS, followed by a 15-min incubation in 0.1% H.O,. Tissue was then put in 
blocking solution, made as above, for 2 h. Following this, tissue was incubated in the 
second primary antibody, a rabbit polyclonal OT antibody (1:3000; Peninsula, Belmont, 
CA), overnight at room temperature. The protocol for the third day was identical to that 
for the second day, with the exception of the ABC concentration, which was 0.05% for the 
cytoplasmic antigen, and the DAB solution, which did not include Ni^SO+j and resulted in a 
brown immunoreaaive product. 
Analysis 
The brain sections were analyzed by using a Zeiss Axiophot microscope and an 
IBAS-20 image analysis system. Thirty equally spaced sections from the mid- and fore-brain 
were analyzed for all rats in the control and experimental groups. Sections were viewed, 
without knowledge of treatment group, under the light microscope for areas of Fos-like 
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immunoreactivity (Fos-IR). The areas of the brain expressing Fos-ER were delineated by 
using anatomical  landmarks in  the  coronal  plane and a  stereotaxic  at las  of  the  rat  brain [37] .  
The Fos-ER was quantified by using a protocol similar to that used previously to quantify 
the number of Fos-IR estrogen receptor containing cells in the brain [35,38], by counting the 
total number of immunoreactive nuclei/specified area. The brain sections were viewed on a 
Zeiss Axiophot microscope at 12.5X, and the nuclei containing Fos-ER were discriminated 
from those not exhibiting Fos-ER by using an EBAS-20 image analysis system. The regions 
examined were the SON [37; SO plates 21-25], PVN [37; Pa plates 23-26], SFO [37; plates 
21-24] and the retrochiasmatic supraoptic nucleus (SOR) [37; plates 26-30]. The total 
unilateral field area of each region, per individual 40 |am seaion, was determined as well as 
the number of immuno reactive nuclei within each unilateral field area. The data obtained 
were then statistically analyzed with a Student's f-test. Values were deemed statistically 
significant if p < 0.05. 
The double label study looked for localization of Fos- and OT-ER in the same cells. 
Coronal brain sections mounted serially onto slides were analyzed at lOX and 40X on the 
light microscope. Because oxytocin's primary site of synthesis is in the SON and PVN, 
these were the only brain regions examined for double labeled cells. 
RESULTS 
Localization of Fos-IR 
Prominent Fos-ER was apparent within the SON, PVN and SFO of the relaxin-
treated animals. In addition to these three regions, occasional cellular nuclei exhibiting Fos-
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ER were seen in the following brain regions: cortex, periventricular hypothalamic nucleus, 
paraventricular nucleus of the thalamus, arcuate and retrochiasmatic supraoptic nuclei, 
supramammary decussation, lateral and medial geniculate nuclei, central gray, and various 
regions of the amygdala. Fos immunoreactivity was comparable in these regions between 
the two treatment groups. Although a significant difference was not obvious in the SOR, 
the amount of immunoreactivity within the nucleus was determined; there was not a 
statistically significant difference between the two groups (data not shown). 
Quantification of Fos-IR 
Fos immunoreactivity was abundant in the SON, PVN and SFO (fig. 1B,D,F) 2 h 
following relaxin treatment, whereas Fos-IR was virtually absent in the saline-treated 
controls (fig. 1A,C,E). Because the SFO varies significantly in size, from rostral to caudal, it 
was divided into rostral and caudal parts for statistical analysis. Both parts of the SFO, as 
well as the SON and PVN displayed immunoreactive nuclei evenly distributed throughout 
the respective region. Results of the quantification of the Fos-ER demonstrated a significant 
difference between the two treatment groups in the SON (t = 4.7, p<0.01), PVN (t = 4.1, 
p< 0.01) and both parts of the SFO (rostral: t= 19.1, p< 0.0001; caudal: t=10.6, 
p < 0.0002), but not in the SOR (t= 1.9, p < 0.1). In order to demonstrate that the areas 
under study were not significantly different in the two groups, the average total unilateral 
field area of each region was determined. There was not a significant difference between 
groups in the averages of the field areas that were evaluated for any of the 4 regions shown 
in fig. 2. Therefore, it was not necessary to take differences in total field area into 
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consideration when calculating the average number of immunoreaaive nuclei per field area. 
Fos and OT double label study 
Oxytocinergic cells were found throughout the SON and in the magnocellular 
PVN. Brain sections from each animal were carefully examined under the light microscope, 
to approximate the number of cells in which both OT- and Fos-IR were located. Because of 
the lack of a technique for quantifying the exaa number of cells in which two non-
fluorescing dyes are located in thick tissue sections, no statistical analysis was performed on 
these observations. Within the SON, there was a high degree of cellular coexistence of Fos-
and OT-IR in the relaxin-treated rats. A majority of the magnocellular cells in the rostral 
and caudal PVN also showed coexistence of OT- and Fos-IR (fig. 3A and B, respectively); 
however, many of the parvocellular nuclei in the caudal portion of the PVN were positive 
for Fos and not for OT (fig. 3B). As in the single-label study for Fos, very little Fos-IR was 
seen in the control animals (fig. 3C). In one of the animals receiving isotonic saline, several 
of the nuclei within the caudal PVN were Fos immunoreactive, suggesting that additional 
factors may have also induced c-fos in animals under study. 
DISCUSSION 
This study demonstrates that Fos-ER is visualized in the magnocellular hypothalamic 
system, as well as in the SFO, following i.v. administration of relaxin. Significant differences 
in the amounts of Fos-IR seen between the experimental and control groups, were found in 
the SFO, PVN, and SON. Cells of the SON and PVN produce and secrete OT, and relaxin 
increases the release of OT, as well as increasing the electrical activity within OTergic cells 
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of the SON [16]. Furthermore, results from the double label IHC study demonstrate that 
many of the OTergic cells within the SON and PVN express Fos after relaxin 
administration, suggesting that i.v. relaxin alters transcriptional activity within OTergic 
cells. 
The use of Fos as a marker of transcriptionally or synaptically activated neurons has 
been previously reviewed [23]. However, it is imperative to acknowledge the limitations of 
interpreting the immunohistochemical localization of Fos as a marker of transcriptional 
activity within OTergic neurons. The AP-1 site must be bound by a dimer to be activated, 
and Fos is only stable as a heterodimer with Jun. Both of these proteins are present in high 
levels following cellular stimulation [22], and although Jun wasn't directly localized in this 
study, the antibody utili2^d precipitates not only the 62 kD Fos protein, but the Fos/Jun 
complex [39]. However, due to significant post-translational modification [23] resulting in 
proteins ranging from 55 to 72 kD, it is unclear in which form Fos is found in high 
concentrations following relaxin stimulation, and if that form is adequately recognized by 
the antibody. The ability of the Fos/Jun complex to bind to the OT gene is uncertain. 
There is a sequence in the OT gene which differs by one base from the AP-1 site [40,41]. If 
Fos is unable to act as a transcription factor at this site, Chan et al. [42] have previously 
discussed Fos' ability to interact with other cellular components, and in that way alter 
cellular output. It should also be pointed out that Fos has been identified as a transcription 
factor for proenkephalin [43], which is also a product of OTergic cells. 
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Fos is generally regarded as a transcription factor, induced by environmental signals. 
The signal studied in the present experiment was relaxin; previously shown to not only 
bind to cells of the SON and PVN [8], but to affect the electrophysiology of these neurons 
[16]. As demonstrated in this experiment, relaxin results in an expression of Fos in the 
hypothalamus. Due to the acute release of OT following relaxin administration [16], it is 
possible that Fos is responding to the decreased amount of stored OT, by activating the 
transcription of oxytocin messenger. 
Fos is found in activated cells from approximately 30 min postactivation to about 8 
h. It reaches its peak concentration at about 90-120 min [23,24]. For this reason, Fos is a 
useful indicator of early, yet transient, cellular activation. It has been previously used to 
locate OTergic neurons activated in response to suckling pups [44,45]. Other neurons have 
shown Fos-IR following stimuli such as osmotic stress [24,25], sexual activity [26], and 
peptide administration [27,28,45]. Our unpublished data indicate that 
intracerebroventricular injection of relaxin in rats activates c-fos, resulting in the expression 
of Fos in nuclear regions, including the SON and PVN. The study described here 
demonstrates that i.v. administration of relaxin is also a stimulus for the activation of c-fos. 
The amount of Fos-IR in the PVN varied among animals receiving isotonic saline; 
however, the average number cells exhibiting Fos-IR for all control animals was 
significantly smaller than that in animals receiving relaxin. The limited variability in Fos 
expression seen within the control group can be explained by differences in animal response 
to the stress of being handled, because stress has been shown to induce Fos-ER in the 
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hypothalamus [46]. In the relaxin group, the parvocellular PVN has numerous non-OTergic 
cells expressing Fos (fig. 3B), which might also be activated because of individual differences 
in the response to stress. However, cells in the PVN are also responsible for producing 
vasopressin, which is released in response to relaxin [17,18]. Therefore, the non-OTergic Fos 
immunoreactive cells in the parvocellular PVN of relaxin-treated animals may be 
responding to stress, may be vasopressinergic cells responding to relaxin, or may be cells 
responsible for synthesizing other peptides not yet shown to be activated by relaxin. 
Fos immunoreactivity in the SFO was almost exclusively seen in the group of 
animals receiving relaxin. The SFO is a circumventricular organ involved in maintaining 
water balance, and is therefore sensitive to osmotic changes. As mentioned previously, 
osmotic stress has been shown to activate Fos; however, testing with an osmometer showed 
only a minute difference between the osmolarity of isotonic saline and relaxin (data not 
shown). Therefore, Fos should not have been induced in the SFO of relaxin-treated animals 
in this study in response to a change in the osmolarity of the blood. Previous studies have 
shown that lesions of the SFO negate the effects that relaxin has on blood pressure [15], 
which demonstrates that relaxin can act at the level of the brain to exert effects on the 
periphery. Autoradiographic binding studies have also shown that the SFO has a high 
concentration of binding sites for relaxin [8]. Interestingly, connections between the SFO 
and SON have previously been shown to exist [46], and relaxin preferentially activates these 
connections over conneaions between the SFO and other areas of the brain [47]. Because 
the SFO has an incomplete BBB, and relaxin is too large to pass through the BBB, it is 
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possible that relaxin's actions are mediated through the SFO. But, there are also relaxin 
binding sites in other areas of the brain, including the PVN and SON [8], and therefore a 
question as to how it reaches these sites. Relaxin could be acting directly on the SON and 
PVN as a neurotransmitter from the SFO following endocytosis by the cell bodies of the 
SFO and transport down the axons. On the contrary, relaxin could be acting indirectly on 
the SON and PVN by eliciting an action potential in the cells of the SFO that project to the 
SON and PVN. Or, relaxin transported into the CSF from the SFO, may reach the SON 
and PVTvf. Relaxin mRNA has been found in discrete regions of the rat brain, however, 
such as the anterior olfactory nucleus, taenia tecta, and the hippocampus [10], which 
supports the idea that relaxin is synthesized within the brain and from there transported to 
its areas of action in other regions of the brain. 
Previous studies have shown that estrogen priming is necessary to obtain the optimal 
action of relaxin in relaxing the pubic symphysis in guinea pigs and mice [1]. It is possible 
that the action of relaxin in the brain is also facilitated by estradiol. Estrogen receptors are 
found in the brain of rats, including areas within the hypothalamus. The rats in the present 
study received timed-release pellets containing 4.2mg of 17b-estradiol. This has been shown, 
when used in conjunction with progesterone replacement [30,31], to sustain adequate blood 
levels of these ovarian steroids to maintain pregnancy following ovarieaomy [32]. 
Producing pseudopregnant rats and ovariectomizing them before the challenge with relaxin 
might produce an answer to the necessity of estrogen in facilitating the effects of relaxin in 
the brain of pregnant rats. 
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In summary, we have demonstrated that i.v. relaxin administration results in 
abundant Fos-ER within the SON, PVN and SFO. Because Fos can be a marker of 
transcriptional activation, these findings begin to define a role for relaxin as a signal for cells 
to alter their transcriptional activity. It has already been shown that relaxin increases DNA 
synthesis in porcine granulosa cells [49]. The present study is the first presentation of 
evidence that relaxin may have the ability to alter activity of OTergic neurons at the DNA 
level. In addition to the response that OTergic cells show to relaxin by altering their release 
of OT, as has been previously shown, this study indicates that relaxin could be involved in 
the synthesis of OT or other products of OTergic cells. 
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Figure 1. Photomicrographs of coronal sections of rat brain. Fos-like immunoreactivity is 
represented by black stained nuclei in the isotonic saline (A,C,E) relaxin (B,D,F) treated 
animals in the SON (A,B)) PVN (C,D), and caudal SFO (E,F). Abbreviations: oc = optic 
chiasm, 3V = third ventricle. Scale bars represent 20 |j.m. 
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Figure 2. The effects of intravenous relaxin administration on the average number of nuclei 
displaying Fos-ER in each of the four regions: rostral subfornical organ (RSFO), caudal SFO 
(CSFO), supraoptic nucleus (SON), and paraventricular nucleus (PVN). Numbers represent 
averages from counts taken unilaterally (in paired regions). On average, ten field areas in the 
PVN were examined per animal, fourteen field areas per animal in the SON, two field areas 
per animal in the RSFO, and three field area per animal in the CSFO. The average number 
of Fos immunoreactive nuclei per field area, in animals receiving relaxin, is represented by 
che solid bars. The hatched bars indicate the average number of nuclei exhibiting Fos-IR per 
field area in the isotonic saline treatment group. In relaxin treated animals, the number of 
Fos-like immunoreactive cells is significantly greater than in the relaxin-treated animals in all 
four of the brain regions presented here: * - p<0.01; ** - p< 0.0002; *** - p< 0.0001. 
Figure 3. Double label photomicrographs depicting the dark Fos-like immunoreactive 
nuclei and brownish gold colored OT-like immunoreactive cytoplasm. A: rostral 
paraventricular nucleus (PVN) demonstrating colocalization of Fos- and OT-ER; B and C 
represent the caudal PVN: B from a relaxin-treated animal, illustrating colocalization of Fos-
and OT-ER, and C from a control animal, illustrating the lack of Fos-IR within OT 
immunoreactive cells. Abbreviation: 3V=third ventricle. Open arrows point to examples of 
cells with coexistence of Fos- and OT-ER. Scale bar = 20 p-m (A), 50 |J.m (B,C). 
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CHAPTER 4 
EFFECT OF RELAXIN ON THE TRANSCRIPTION OF OXYTOCIN IN 
THE MAGNOCELLULAR HYPOTHALAMUS OF THE PREGNANT RAT 
A paper to be submitted to Neuroendocrinology 
Patricia A Heine, Carol D Jacobson and Lloyd L Anderson 
ABSTRACT 
Relaxin administered to late pregnant rats induces the expression of Fos in 
oxytocin producing cells of the hypothalamus, indicating a change of cellular activity 
within these neurons. The objective of the present study was to determine if the change in 
cellular activity was due to an alteration in the amount of oxytocin mRNA present in 
these cells following relaxin administration. Primigravid rats were ovariectomized on 
gestational day 9 (g9). Pregnancy was maintained using progesterone and 17P-estradiol 
implants. There were three control groups of rats; one which had no surgery, one which 
had a sham surgery, and one which was ovariectomized and received relaxin replacement. 
Rats were killed either on gl9, g21 or g 23. Their brains were removed and prepared for 
in situ hybridization. OT mRNA levels were visualized using a "S labeled oligonucleotide 
probe. Slides with hybridized brain sections were exposed to radiographic film. Images on 
the film were quantitatively analyzed for differences in optical density. The amounts of 
OT mRNA were not different between any of the treatment groups or any of the 
gestational time points analyzed. 
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INTRODUCTION 
Control of the synthesis and release of oxytocin (OT) during pregnancy is not 
fully understood. Its release depends not only on a self regulating positive feedback loop, 
but also upon local opioids [1, 2]. The factors controlling the synthesis of OT may also 
involve opioid control [3]. 
Relaxin and OT are both hormones which play integral roles in pregnancy and 
parturition. In rats, relaxin is found nearly exclusively in the corpora lutea during the 
latter half of pregnancy [4, 5]. Pregnancy in rats lasts 23 days, and relaxin is first detectable 
in the serum at 10 days of gestation (glO) [6]. It plateaus from gl4 to gl9 and then rises in 
two peaks 60 and 24 h prior to parturition [7]. It is necessary for remodeling the collagen 
in the reproductive tract which allows for passage of the fetuses [6], and also for 
developing the mammary apparatus [6]. Oxytocin is released in a diurnal rhythm [8] 
except during physiological states which demand its release such as parturition, when it is 
released in boluses to promote uterine contraction [9]. 
The interaction between OT and relaxin has been studied in both pigs and rats. 
Although not completely understood, several studies have examined the effect of relaxin 
on the release of oxytocin. In pigs, relaxin has been shown to have no effect on circulating 
OT concentrations during lactation [10]. In ovariectomized nonpregnant rats, relaxin 
appears to increase the release of OT into the circulation [11]. A study using pregnant rats 
showed that this effect was attenuated in late pregnancy [12], the findings of which were 
supported by a study demonstrating that the absence of relaxin decreases the opioid 
inhibition of OT release [13]. Several studies have looked at the relationship between 
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relaxin, OT and opioids [14-19], The relationship of relaxin to the synthesis of OT, 
however, has not been thoroughly studied. 
The relationship between relaxin and OT is best studied at the end of pregnancy 
when both hormones are found in the circulation in high concentrations and their 
relationship is dynamic. In a previous study conducted in our laboratory on late pregnant 
rats [19], indirect evidence pointed toward relaxin's ability to alter OT synthesis. Cellular 
activity within OTergic cells following relaxin administration was visualized using Fos, a 
transcription factor [20], as a marker. Fos binds to the AP-1 site of genes to activate or 
repress transcription [20, 21]. The localization of Fos in OTergic neurons in the previous 
study, therefore, demonstrated that a transcriptional change was occurring, but was not 
conclusive as to the nature of the transcriptional alteration nor the gene being transcribed. 
A further study needed to be designed to directly examine the levels of OT mRNA to 
determine if they were modulated by the presence or absence of relaxin. 
The purpose of this study was to determine if relaxin is directly involved in 
regulating the synthesis of OT in the magnocellular hypothalamic nuclei of the late 
pregnant rat. In situ hybridization for OT mRNA in the brains of late pregnant rats was 
utilized to answer this question. 
MATERIALS AND METHODS 
Animals 
Rats were housed in plastic cages, one per cage, under a 12:12 h light:dark cycle. 
They were fed a rodent diet (Teklad, 6% fat; Madison, WI) and provided water ad libitum. 
All procedures were approved by the Iowa State University Committee on Animal Care. 
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Treatment groups 
This study utilized four different hormone treatments and three different 
gestational stages (fig. 1). The gestational days studied were gl9, 21 and 23. The hormone 
treatments were ovariectomy with progesterone and estradiol replacement (OPE); 
ovariectomy with progesterone, estradiol, and relaxin replacement (OPER); sham 
ovariectomy, in which the animals underwent the same surgical procedure as the OPE 
group, except they maintained their ovaries (S); and a control group which undeiTvent no 
surgery (C). Each of the twelve time by treatment groups had three rats, for a total of 36 
animals in the study. 
Surgery 
Rats were obtained from Harlan Sprague Dawley (Indianapolis, IN). Primigravid 
females (2-4 months old) were housed with males for breeding. Pregnancy was determined 
by observing sperm in the vaginal smear. The day sperm were found was designated gl. 
On g9 rats in groups S, OPE and OPER underwent surgery. Anesthesia was induced and 
maintained using isoflurane (Solvay; Mendota Heights, MN) delivered by an anesthetic 
machine (Fraser Harlake; Orchard Park, NY) through a nonrebreathing system. Rats 
were placed in an enclosed chamber for induction using 3% isoflurane, and were 
maintained for the duration of surgery using 1.5% isoflurane. All anesthetic was delivered 
with oxygen at IL/min. 
Rats underwent bilateral laparotomy for ovariectomy. Incisions were 1 cm long, 
and were closed in two layers using 3-0 Ethilon (Ethicon; Somersville, NJ) in a simple 
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continuous pattern on the muscle layers and staples (Autoclip, 9 mm; Becton Dickenson; 
Sparks, MD) to close the skin. Only rats with at least 6 fetuses were retained in the study. 
During the same surgical procedure animals received hormone replacement, which 
has been detailed elsewhere [22]. Briefly, 4 silastic tubes (Sani-Tech, Inc., LaFayette, NJ; id 
1.5 mm, od 1.9 mm; 52 mm in length) filled with crystalline progesterone (Sigma, St. 
Louis, MO) were placed subcutaneously along the flank through one 2 cm incision over 
the thoracolumbar spinal region, which was closed using staples (Autoclip, 9 mm; Becton 
Dickenson). One silastic tube (Sani-Tech, Inc.; id 1.6 mm, od 3.2 mm, 1.6 cm in length) of 
17P-estradiol (2 |ag; Sigma) was placed subcutaneously at the nape of the neck. 
The estradiol implant was replaced with an implant containing 12 |a.g 17P-estradiol 
on gl8 to mimic the increase in estrogen levels that occur during late pregnancy [22, 23]. 
Progesterone implants were removed early on the morning of g22 to mimic the decline in 
progesterone levels that occurs at luteolysis [22-24]. Rats in the sham group received 
empty implants (progesterone controls) and implants containing sesame seed oil (17-P 
estradiol controls). All implants were sealed using Silastic glue (Dow Corning, Midland, 
MI). The OPER group received an Alzet osmotic pump (Alza Corp., Palo Alto, CA) 
subcutaneously caudal to the scapulae for the delivery of porcine relaxin (0.5 p-l/h for 14 
days = pump rate). Relaxin was put into solution using 0.9% NaCl. Porcine relaxin has 
been proven to be biologically active in rats [6]. 
Tissue Preparation 
Brains from the dams were removed on gl9, 21 or 23 at 0600 h. Rats were lightly 
anesthetized using isoflurane (Solvay) followed by decapitation. Brains were carefully 
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removed from the calvaria, divided into fore- and hindbrain blocks, and quick-frozen in 
isopentane (Fisher Scientific, Pittsburgh, PA). Brains were then stored at -70°C in air tight 
plastic bags until sectioned. Brains were sectioned on a cryostat (Reichart-Jung 2800N) 
into lO-fim coronal sections. Sections were thaw mounted onto poly-L-lysine coated 
slides. Approximately every other section throughout the hypothalamic region was 
mounted. A total of 96 sections was kept from each hypothalamus, divided into 48 rostral 
and 48 caudal sections. There were 8 brain sections on each slide and 6 slides in each of 
the two groups (twelve slides/rat). Brain sections were fixed in 4% paraformaldehyde for 
5 min, rinsed in 0.1 M phosphate buffered saline, and then stored in 95% ethanol (EtOH) 
at -70 ° C until used for in situ hybridization (ISH). 
In situ hybridization 
Prehybridization 
Slides on which brain sections were mounted, were removed from their -70 ° C 
storage in EtOH and allowed to dry in a dust free environment at room temperature. 
One rostral and one caudal slide from one of the three rats in each of the twelve time by 
treatment groups were run together as a hybridization group. The 36 rats were randomly 
assigned to one of three hybridization groups, such that each of the three groups 
contained one rat from each of the twelve time by treatment groups. After the slides were 
dry, a PAP pen (Newcomer Supply, Oak Park, IL) was used to form a hydrophobic ring 
around the periphery of the tissue sections to keep the labeled hybridization buffer on the 
tissue. 
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Probe preparation 
Deoxyribonucleic acid (DNA) oligomers (probes) were synthesized at the Iowa 
State University DNA Facility. Three antisense probes, each 45 bases in length, were 
synthesized for three different regions of the OT DNA. All were from exons, and none 
showed more than a 62% homology with the same area of the vasopressin gene. These 
were designed to compare the labeling patterns produced by each one to ensure the probe 
was labeling OT mRNA. The probe which was used in all of the analyzed work was: 
5'TTGCGCATATCCAGGTCTAGCGCAGCCCTCTTGCCGCCCA3'. This was 
antisense to the OT DNA sequence starting at base 341 [25]. 
Radioactive labeling of the oligonucleotide was utilized. The terminal 
deoxynucleotidyl transferase (TdT) end-labeling protocol was a modification of that 
previously published [26]. One microliter of oligonucleotide at a concentration of 0.3 
pmol/|J.l was added to 2 |j.l 5x reaction buffer (Boeringer Mannheim, Indianapolis, IN), 0.6 
|j,l CoCU (Boeringer Mannheim), 6 |il ^^SdATP (NEN Research Products, Boston, MA), 5 
|il sterile H,0 and 1 |a.l TdT (Boeringer Mannheim). The labeling reaction was carried out 
in a 37 ° C waterbath for 15 min. The reaction was stopped when 35 fj.1 of sterile water 
was added to the mixture. The probe was added to prepared spin columns (Biospin 6 
chromatography columns, BioRad; Hercules, CA) and centrifuged as per product 
specifications. Two microliters of the eluate were evaluated using liquid scintillation 
counting. Probes were only retained if counts were between 50,000-100,000 dpm/|j.l. If 
probes (labeled oligonucleotides) were not used immediately, they were stored at -20 ° C 
for later use. 
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Hybridization 
The protocol utilized for the hybridization was a modification of that previously 
published [26]. Hybridization buffer was composed of 50% formamide (Fluka, 
Ronkonkoma, NY)/4 x SSC/10% dextran sulphate (Sigma). One microliter of probe was 
added to 100 |j.1 of hybridization buffer. Each slide was dipped in hybridization buffer 
prior to the addition of the probe/buffer mixture. This provided a fluid contact allowing 
the probe/buffer to more easily cover the sections on the slide. Approximately 300 |al of 
the probe/buffer mixture was added to each slide. A much cleaner signal was obtained 
without the use of coverslips, so this step, which is a part of many ISH protocols, was 
omitted in this study. The slides were then placed in a humid chamber (humidified with 
1:1 mixture of water and formamide) and incubated at 44 ° C overnight. 
Post-hybridization 
Slides were removed from the humid chamber and washed in 1 x SSC. Probes 
which may have hybridized to the wrong sequence were removed through an incubation 
in Ix SSC at 60°C for 30 min, followed by rinsing in 1 x SSC and 0.1 x SSC. Slides were 
then dehydrated and allowed to dry. Slides were kept in their hybridization groups (one 
slide from an animal in each of the twelve treatment groups) for image production which 
was accomplished by taping the slides to paper and exposing them to X-ray film (XAR-5, 
Eastman Kodak Co., New Haven, CT). In addition to the 12 experimental slides, each 
film had a set of brain paste standards for densitometric calculations, and two controls. 
The protocol for making the brain paste standards was followed exactly as previously 
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published [26]. Optimal exposure time for the slides on the X-ray film was 2 h. The film 
was developed using an automatic processor (Eastman Kodak). 
Following exposure to film, the slides were dipped in emulsion. NBT-2 emulsion 
(Kodak Eastman) was brought to 42°C and diluted 1:1 with ddH20 in a dark room. The 
liquified emulsion was transferred to a slide dipping chamber and all of the slides were 
dipped in the emulsion and allowed to dry in a dark box for 5 h. They were then placed in a 
light proof slide box at 4°C for 24 h. The slides were developed for 2 min in Dektol (Kodak 
Eastman) at 17°C. rinsed in ddH20 and fixed for 20 min. Following fixation, slides were 
rinsed in running water for 1 h, during which the emulsion was removed with a razor blade 
from the back of the slides. Slides were then coimter stained with a 1 % neutral red solution 
(Fisher Scientific), dehydrated through graded EtOH. cleared with xylene (Fisher Scientific) 
and coverslipped with Permoimt synthetic mounting media (Fisher Scientific). Figure 3 
demonstrates the labeling obtained through this technique. 
Image analysis 
The SON [27, SO plates 21-25] and PVN [27, Pa plates 23-26] were the brain areas 
studied. To analyze areas on the radiographic film which corresponded to the OT 
producing SON and PVN, images were acquired by the Iowa State University Image 
Analysis Facility using and Agfa Arcus 11 flatbed scanner (Wilmington, MA) attached to 
an Apple 8500 Power PC (Cupertino, CA). The brain paste standards (dpm/mg) on each 
film were used with the internal scaling features of the software to accurately calibrate the 
densitometric data. The film images were interactively thresholded and then edited to 
isolate the SON and PVN for measurement. These regions were then measured to obtain 
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the densitometric reading. A mean value for all eight coronal brain sections on each slide 
was determined for both the SON and PVN. To avoid researcher bias, the treatment by 
time group to which each slide belonged remained coded until after the image analysis 
was completed. 
For the purpose of illustration, a color table was created for each set of images 
using Adobe Photoshop (San Jose, CA) in which the grey values, corresponding to the 
various density levels of the brain paste standards, were assigned a specific color (Fig. 4). 
The same color table was applied to each brain section on the film. 
Controls 
Two controls were used in this experiment. The first control was a competitive 
control to assess for non-specific binding. Twice as much unlabeled as labeled 
oligonucleotide was added to the probe/buffer mixture to compete with the labeled 
oligonucleotide for binding sites. The second control was checking to determine if the 
OT gene actually was what was being labeled. This was accomplished by using all three 
probes synthesized against different areas of the exons of the OT gene to observe if the 
resultant labeling patterns were similar. The first control was exposed to film along with 
each of the hybridization groups. The second control was run initially to determine 
whether or not the probe was labeling OT mRNA. 
Statistical analysis 
The mean dpm/mg value for each slide on the film was uncoded and placed into 
its proper time by treatment group. There were two values from each animal (one from 
the more rostral brain sections and one from the more caudal brain sections) and three 
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animals per group. There was one exception in which there were only two animals 
because one rat managed to remove her estradiol implant, resulting in fetal resorbtion, so 
her brain was not used in the study. A mean dpm/mg value was calculated from the six 
individual mean values for the each of the twelve treatment groups. This was conducted 
separately for the two regions (SON and PVN). An ANOVA was used to determine the 
statistical significance, which was set at p < 0.05. 
RESULTS 
This probe appeared to be very specific, as there was very little binding to any 
areas of the brain other than the hypothalamus. Because of this, the outline of the brain 
was not at all apparent in the figures, but was artificially drawn in for the purpose of 
orientation. 
The average fetal survival for the rats which were exposed to relaxin was 13.2 pups 
± 2.86 for gl9, 10.7 pups ± 2.41 for g21 and 10.6 pups ± 4.77 for g23. Rats which were not 
exposed to relaxin had a fetal survival rate of 16.3 pups ± 2.14 for gl9, 12.3 pups ± 2.89 for 
g21, and 12.0 pups ± 4.36 for g23. As was previously noted [22], rats in the OPER group 
had the lowest fetal survival rate of the four treatment groups. 
Controls 
The binding of the ^^S labeled oligonucleotide probe to the OT mRNA was greatly 
decreased when it was incubated with the unlabeled oligonucleotide, as compared to a 
brain section which did not have the unlabeled probe added to the incubation. Figure 2 
demonstrates the similarity in the labeling from the three different probes, indicating that 
the probes are specific for OT mRNA. 
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Treatment groups 
The dpm/mg values did not show a statistically significant difference in either the 
SON (p > 0.05) or the PVN (p > 0.05) between the treatment groups (Fig. 5) or the 
gestational time points (Fig. 6). 
DISCUSSION 
The present study showed that relaxin does not play a role in promoting the 
synthesis of OT in the brain of the late pregnant rat. Results of ISH for OT mRNA 
indicated that there was no significant difference in the dpm/mg value in either the SON 
or PVN when comparing either treatment groups or gestational time points. The same 
mean dpm/mg value was present in rats exposed to relaxin as those not exposed to 
relaxin. Likewise, the mean dpm/mg value was not altered in response to the proximity 
of parturition. 
The hypothesis of this study was that relaxin plays a role in the synthesis of OT 
during pregnancy. It was expected that the three control groups (C, S, OPER), which 
were all exposed to relaxin, would all show a higher dpm/mg value than the OPE group 
which did not have any circulating relaxin. To closely define any differences seen between 
C and OPE, the sham groups was included to control for changes caused by anesthetic or 
the stress of handling. In addition, the OPER group was included to control for the 
possibility that some ovarian factor other than relaxin was responsible for observed 
differences. As it turned out, all three controls had nearly identical dpm/mg values. 
Surprisingly, the OPE group also had mean dpm/mg values which were not significantly 
different from the controls. Analysis of one of the six hybridization groups alone did 
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show that the OPE group had a lower mean dpm/mg th^ the controls, but this finding 
was not repeated in the other five hybridization groups. 
Previous experiments indicated that OT mRNA concentrations did not increase 
significantly in the antepartum period [28, 29]. This finding was supported in the current 
study. Figure 5 shows that rats from group C from each of the three gestational stages did 
not show significantly different dpm/mg values. This is somewhat surprising in light of 
the imminent demand on the cells to provide sufficient OT to stimulate uterine 
contraction during parturition. Therefore, because neurohypophysial OT is necessary for 
parturition to occur, it is likely that the release of OT is inhibited since its synthesis is not 
mcreased. Relaxin has been shown to aid opioids in their inhibition of OT release [13], so 
perhaps that is the mechanism for increasing stores of oxytocin. 
The lack of effect of relaxin on the presence of OT mRNA concentrations begs 
the question of what the purpose of the Fos is, observed in OTergic cells following 
relaxin administration[19]. The initial assumption woulcl be that Fos is responsible for 
altering the transcription of another gene in the OTergic cells. One candidate is 
preproenkephalin. This has previously been shown to have an AP-1 site [30] and its 
protein produa is colocalized in granules with OT [31]. However, little proenkephalin is 
expressed in magnocellular neurons [32]. Another gene that Fos could be regulating is the 
one which encodes for the |J.-opioid receptor. This receptor appears to be responsible for 
the inhibition of OT release in late pregnancy [33], as th^ K-opioid restraint seen in early 
pregnancy is reduced [34]. Another possibility is that Fo.« is coincidentally present due to 
a change in the firing characteristics [35] of the OTergic cells in response to the relaxin 
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[11] and is not actively involved in any transcriptional regulation. However, relaxin's 
ability to release OT is attenuated in late pregnancy [12] and therefore presumably the 
firing rate of the OTergic cells is also less sensitive to relaxin during this time. This 
indicates that Fos' expression as a result of relaxin administration may not be due to a 
change in the firing pattern. Additionally, it has been shown that in magnocellular 
neurons of the hypothalamus, synaptic activation is necessary for the expression of Fos, 
not a change in spike activity [36]. 
The OT gene does have an estrogen response element [37], indicating that its 
transcription may depend on the presence of estrogen. Interestingly, many of the relaxin 
induced changes seen during pregnancy are enhanced by the presence of estrogen [6]. 
Perhaps this is also the case in regard to the production of OT, but estrogen likely plays a 
more important role than relaxin. However, estrogen's role will be difficult to sort out 
due to the inability to maintain pregnancy without its presence. Interestingly, 
intracerebroventricular administration of relaxin to male rats also results in Fos 
expression in the SON and PVN [38], indicating that Fos' actions are not necessarily 
codependent on circulating female hormones. 
In summary, relaxin does not appear to modulate the presence of OT 
mRNA within the SON or PVN during late pregnancy. Exactly why relaxin stimulates 
the presence of Fos in these cells remains unknown; several hypotheses have been 
discussed. A final determination will depend on future studies, perhaps looking at rhe role 
of opioids and their receptors or estrogen and its receptors. 
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Figure 1. Diagram of the treatment design. The length of the bars indicates the gestational date on 
which rats were sacrificed. For details on hormone replacement, see Materials ami Methods. 
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Figure 2. Scanned images from x-ray film exhibiting coronal brain sections 
showing the SON and PVN. A, B and C are examples of the three different oligo 
probes made against different areas of the OT gene. Notice the similarity in 
labeling pattern. SON = supraoptic nucleus, PVN = paraventricular nucleus 
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Figure 3. Photomicrographs of coronal brain sections exhibiting the SON (A) and 
the PVN (A and B). The tissue was exposed to ^^S-labeled oligonucleotides 
designed to bind to OT mRNA. The slides were then dipped in emulsion and 
developed to demonstrate the labeled area, which is represented by the black 
areas. Neutral red was used as a background stain. Notice the specificity of the 
labeling to the OT producing areas of the hypothalamus. 3V= third ventricle, SON 
= supraoptic nucleus, PVN = paraventricular nucleus 

Figure 4. Pseudocolored brain paste standards. Red = 101,500 dpm; orange = 
62,000 dpm; yellow = 58,000 dpm; green = 38,500 dpm; blue = 24,000 dpm; 
purple = 13.000 dpm; pink = 5,500 dpm. 
\ 
Figure 5. Pseudocolored prints of representative brain sections from the four different treatment 
groups. A = an ovariectoniized animal that received relaxin replacement, B = an ovariectomized animal 
that received only progesterone and estradiol replacement, C = a sham ovariectomized animal, D = a 
control animal which underwent no surgery. Note that the color, which represents the optical density (a 
measure of the density of the OT mRNA), is essentially the same in all of the treatments. An 
approximate outline of the brain was drawn for the purpose of orientation. SON = supraoptic nucleus, 
PVN = paraventricular nucleus 

Figure 6. Pseudocolored prints of representative brain sections from animals 
representing the three different time points. A = gl9, B = g2I,C = g23. Note the 
similarity in color between the three groups. An approximate outline of the brain 
was drawn for the purpose of orientation. SON = supraoptic nucleus, PVN = 
paraventricular nucleus 
S (  ) \  
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CHAPTER 5 
GENERAL CONCLUSIONS 
General Summary 
The first study investigated the relationship between OT, PRL and relaxin in the 
pregnant pig. In midgestational gilts, relaxin appeared to mildly increase the circulating 
levels of prolactin and significantly increase the levels of oxytocin. In late gestational gilts, 
however, there was no apparent effect of exogenous relaxin on the circulating 
concentrations of OT or prolactin. The most interesting and prominent result arising 
from this study was an unexpected large transient rise in the circulating levels of both OT 
and PRL following the removal of the gilts' ovaries. The rise in both hormones was 
statistically significant, however the rise in OT was much more remarkable. The 
circulating levels of both PRL and OT remained elevated for only a short period, followed 
by a return to baseline levels. The study was designed to determine the effects of the iv 
administration of relaxin on OT and PRL, and the most prominent finding was incidental. 
Its unplanned nature, however, makes this discovery no less important. The lack of relaxin 
on circulating concentrations of OT and PRL fortuitously led us to a new hypothesis, 
that relaxin in the antepartum period is acting to inhibit the premature release of OT from 
its stores in the neurohypophysis. A study in pregnant rats indicated that the inhibitory 
effect of opioids on the release of OT from its nerve terminals in the neurohypophysis is 
decreased in rats after ovariectomy (Way et al., 1993). 
The second study turned to rats to look at the effect of relaxin on the somata of 
OTergic neurons in the hypothalamus. The iv administration of relaxin to late pregnant 
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rats increased the expression of Fos, used as a marker of cellular activation, in the 
magnocellular OTergic neurons of the SON and PVN as well as within the SFO. These 
results indicated that relaxin had an effect on the cellular activity within OTergic neurons 
as well as within the subfornical organ. 
The third study further looked at the effect of iv relaxin administered to late 
pregnant rats on the synthesis of oxytocin. On three different days during late pregnancy, 
rats were sacrificed to determine the levels of OT mRNA expressed in the SON and PVN 
of the hypothalamus in response to the presence or absence of endogenous relaxin or the 
addition of exogenous relaxin. Findings from this study indicated that relaxin does not 
have an effect on the transcription of OT mRNA in late pregnancy. 
Collectively, the findings from these studies show that during the antepartum 
period, relaxin appears to be inhibiting a premature release of OT from the 
neurohyphophysis (most likely through synergistic acitivity with opioids which are 
known inhibitors of OT release), as well as promoting activity within the OTergic 
neurons of the hypothalamus. However, the activity seen in the SON and PVN does not 
appear to be an increase in the transcription the OT gene. 
General discussion 
The present studies were designed to further our understanding of the relationship 
between OT and relaxin in late pregnancy. We determined the effects of relaxin and the 
lack thereof on the circulating concentrations of OT and prolactin in pregnant pigs. We 
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have also investigated the effect of relaxin on OTergic cellular activity and the synthesis of 
oxytocin in late pregnant rats. 
Centrally, the physiological and anatomical relationships of OT and relaxin have 
been studied in the rat, and the physiological relationship has been investigated in the pig. 
In rats, relaxin enhances the release of OT (Dayanithi et al., 1987; Way and Leng, 1992) 
except during pregnancy when this relationship is attenuated (Parry et al., 1994), and 
relaxin binding sites are also found in the SON and PVN of rats (Osheroff and Phillips, 
1991). In the pig, relaxin has been shown to have no effect on the circulating levels of OT 
during lactation (Porter et al., 1992). These relationships in addition to facts and queries 
concerning each hormone individually led us to design the studies within this dissertation. 
Oxytocin is the most powerful uterotonic agent known. However, its potency is 
regulated by the concentration of myometrial OT receptors. Oxytocin receptors in the 
uterus are upregulated by an abrupt decrease in circulating progesterone concentration just 
prior to the onset of labor (Alexandrova and Soloff, 1980), and circulating OT does not 
increase until after labor has started (Giraldi et al., 1990, Forsling et al., 1979). Premature 
release of OT, therefore, would not initiate labor unless the uterus was primed, and would 
reduce the amount of OT available for fetal expulsion during parturition. The regulation 
of the prevention of this premature release of OT is of interest. 
Although control over the release of OT during parturition has been well 
documented, control over its release in late pregnancy is not as well understood. There 
appears to be some inhibition of OT release through endogenous opioids. Dynorphin is 
stored and released with vasopressin from the neurohypophysis. It acts on K-opioid 
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receptors in the neurohypophysis to inhibit the release of oxytocin (Bondy at al., 1989). 
Beta-endorphins exhibit a diurnal rhythm opposite that of OT in late pregnant women, 
suggesting that an increased level of circulating P-endorphins prevents the release of 
oxytocin (Lindow, et al., 1996). Work presented in Chapter 2 on pregnant pigs shows that 
removal of relaxin results in a mass release of OT, followed by its return to baseline levels. 
This suggests that relaxin may act as a tonic inhibitor of OT release in late pregnant pigs. 
In support of this, studies in the rat indicate that relaxin's ability to cause a release of OT is 
attenuated in late pregnancy (Parry et al., 1994). Additionally, the opioid restraint of OT is 
decreased in ovariectomized rats (Way et al., 1993). This implicates relaxin as a modulator 
of the opioid restraint seen during pregnancy. 
Activity within OTergic perikarya can be documented using the expression of 
proto-oncogenes as markers of cellular activity. One such gene is c-fos, which has been 
shown to be activated in OTergic cells by various stimuli (Flanagan et al, 1993; Verbalis et 
al, 1991; Giovannelli et al, 1990). Q-fos expresses its protein Fos in response to 
depolarization and calcium influx (Morgan and Curran, 1986). This depolarization can 
result from numerous stimuli. Expression of Fos in the magnocellular hypothalamus is not 
activated by changes in spike activity, but rather by changes in synaptic activity (Luckman 
et al., 1994). In light of the findings from Chapter 3, one such stimulus could be the 
binding of relaxin to receptors on the cell membrane. Although the relaxin receptor has 
not been characterized, Osheroff and Phillips (1991) have shown that the SON and PVN 
do have binding sites for relaxin. In this way, relaxin could be activating c-fos within the 
OTergic neurons. 
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What role is Fos playing within the OTergic neurons? Fos is a transcription factor. 
It can act either to stimulate or repress transcription (Sassone-Corsi et al., 1988). It alters 
transcription by binding as a heterodimer with Jun (the protein product of the related 
proto-oncogene c-jun) to the AP-1 site in DNA (Morgan and Curran, 1991). Many genes 
have an AP-1 site. The OT gene has a site which differs from the AP-1 site by only one 
base (Fenelon et al., 1993). Also found within OTergic neurons is the gene for 
proenkephalin (Lightman et al., 1987), which has an AP-1 sequence (Sonnenberg et al., 
1989). Because relaxin does not appear to be altering the transcription of OT, as defined in 
Chapter 4, it may be acting on proenkephalin, which binds to |4.-opioid receptors. These 
receptors are believed to be involved in OT restraint in late pregnancy (Douglas et al., 
1995). Alternately, relaxin could be acting through Fos to upregulate the expression of the 
)i-opioid receptors themselves. 
The primary site in which the OT gene is found is within the magnocellular nuclei 
of the hypothalamus. It is also found in the uterus of the rat during late pregnancy 
(Lefebvre et al., 1992) and in the ovary of the cow during pregnancy (Musah et al., 1990). 
Using ISH, OT mRNA levels in the SON and PVN have been shown to be increased in 
late pregnant rats over those found in virgin rats (Miller et al., 1989). And, although OT is 
present in the uterus, neurohypophysial OT is necessary for parturition to occur 
(Luckman et al., 1993). 
Interaction of relaxin and oxytocin 
Circulating relaxin acts in several ways in the prepartum female. It keeps the uterus 
quiescent and remodels the collagen of the pelvic ligaments and reproductive tract to 
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accommodate for passage of the fetus. In the rat and pig, relaxin's concentration in the 
circulation is steady until the antepartum period at which time it peaks and then returns to 
its baseline level (for review see Sherwood, 1994). It is unclear what role this peak release 
of relaxin plays. It is tempting to postulate that the interhormonal relationship between 
relaxin and OT is temporally active around this antepartum period. 
The mass release of relaxin at the end of pregnancy may be acting as a final restraint 
mechanism to prevent the release of oxytocin. Results from Chapter 2 suggest that this 
may be a mechanism in pigs, and a study from another laboratory showed similar findings 
in ovariectomized rats (Way et al., 1993). No studies have been done to determine whether 
blocking peripheral relaxin exclusively during the antepartum period affects circulating 
OT concentrations or the birthing process. Blocking peripheral relaxin throughout 
pregnancy prolongs gestation as well as lengthening the time of parturition and the 
amount of straining. This is primarily due to the lack of cervical ripening. However, a 
recent study by Summerlee (1998), demonstrated that intracerebroventricular (icv) 
administration of a relaxin monoclonal antibody to late pregnant rats allowed parturition 
to occur earlier than it otherwise would, as well as proceeding more quickly. The author's 
explanation was that central and peripheral relaxin systems must be separate. I postulate 
that rather than separate relaxin systems, the large increase in circulating relaxin during the 
antepartum period was blocked by the monoclonal antibody when it entered the CSF. 
Although it is possible that the source of relaxin in the brain is central (Osheroff and Ho, 
1993; Gunnersen et al., 1985), relaxin can gain access to the CSF (Parry et al., 1991). With 
the higher circulating amounts of relaxin during this antepartum period, it would seem 
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likely that relaxin is also entering the CSF in higher concentrations. Likewise, it is 
unlikely that the antepartum release of relaxin has no physiological effect. I therefore 
postulate that the antepartum elevation in relaxin is acting to prevent the premature 
release of OT in late pregnancy. 
How exactly is relaxin preventing the release of OT? Indeed, the relaxin receptor 
has not yet been characterized, so we do not know if the nerve terminals in the 
neurohypophysis have relaxin receptors to enable relaxin to act in this way. We do know, 
however, that relaxin has binding sites in the SON and PVN (Osheroff and Phillips, 1991) 
of non-pregnant rats, but we do not know what happens to these binding sites during 
pregnancy. The neurohypophysis has not been studied for relaxin binding sites, however 
in vitro experiments do show that relaxin alters the release of oxytocin (Dayanithi et al., 
1987). This indicates that neurohypophysial relaxin receptors modulate these changes. 
We also know that the opioid restraint of OT appears to switch from K-opioid 
receptor restraint in the neurohypophysis during early and mid pregnancy to |J.-opioid 
receptor restraint on the OTergic cell bodies at the end of pregnancy (Leng et al., 1997). 
Dynorphin, co-released with vasopressin from nerve terminals in the neurohypophysis, is 
a K-opioid receptor agonist. It is active in the restraint of OT release during pregnancy. 
This restraint becomes weaker in late pregnancy, at which time |j.-opioid receptors are 
thought to take over the control of OT release (Douglas et al., 1995). These receptors, 
however, are located on the cell bodies, not on the nerve terminals like K-opioid receptors 
(Leng et al., 1997). Likewise, as mentioned previously, relaxin binding sites are found in 
the SON and PVN, where the OTergic cell bodies are located. Therefore, relaxin may be 
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modulating the |j.-opioid receptors found on these cells; perhaps through the expression of 
Fos. Interestingly, in rats the OT receptors in the uterus are not upregulated until 
approximately 8 h prior to parturition, and the circulating peak of relaxin is on a decline 
12 h prior to parturition. This opens a window for the circulating OT to start increasing. 
However, there are relaxin surges during parturition, which causes a problem with this 
hypothesis. There are two possible explanations for this diskumboomeration (Merlin, The 
Sword and the Stone, Walt Disney Productions). First, this could be explained if the 
circulating OT, which binds to OTergic cells (Neumann et al., 1996), changes the 
expression of either the relaxin or the |J.-opioid receptors on these cells. This would 
prevent relaxin or proenkephalin from binding to the cells in high enough quantity to 
prevent the release of ox>T;ocin. A second explanation is theorized by the in vitro finding 
that relaxin potentiates the release of OT from depolarized nerve terminals (Dayanithi et 
al., 1987). This suggests that during times of physiological excitation, such as parturition, 
the neurohypophysial nerve terminal release of OT would be enhanced by the presence of 
relaxin. 
Conclusions 
There are obviously many postulations involving the possible interaction of relaxin 
and oxytocin. Too much data implicate a relationship to ignore the possibility. However, 
the data available are not conclusive. Specific studies need to be designed to act as the 
connecting pieces for this unfinished jigsaw puzzle. 
There are several future studies I envision to answer the questions raised by this 
dissertation. Initially, it would be worthwhile to conduct relaxin binding studies on the 
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brains of pregnane rats at different points during gestation. The data currently available 
show that relaxin in nonpregnant rats binds moderately to the SON and PVN. How is 
this binding altered during pregnancy? Is it increased in late pregnancy? 
Broader studies using icv and peripheral administration of relaxin antibodies are 
also necessary. Does peripheral administration of a monoclonal relaxin antibody in late 
pregnancy result in the same findings as an icv administration? What if pregnant rats are 
exposed to icv monoclonal relaxin antibody throughout pregnancy instead of just at the 
end? Answering these questions will help identify the source of the relaxin interacting m 
the brain with oxytocin. 
Further investigation is necessary to understand the role of Fos as a messenger for 
relaxin in OTergic cells. Utilizing ISH for proenkephalin and the ^-opioid receptor in the 
SON and PVN of late pregnant rats in relaxin deficient states, may indicate whether or 
not the genes for these two proteins undergo transcriptional changes in response to 
relaxin. 
Lastly, a study should be done to examine the possibility of estrogen modulating 
the transcription of oxytocin. The presence of the estrogen response element on the OT 
gene (Richard and Zingg, 1990) suggests an interaction between these two hormones. 
Estrogen receptors are found in the hypothalamus (Li et al, 1997). To determine the role of 
estrogen in the transcription of OT during pregnancy, icv raloxifene (an estrogen 
antagonist) administration could be used to block the estrogen receptor, and in that way 
prevent activation of the estrogen response element. 
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From these studies, one of the most important conclusions is that not only does 
relaxin act differently in different species, as has been noted before, but it seems to have 
different actions depending on the gestational status of the animal. Therefore, when 
studying hormonal interrelationships, it is important to carefully define the model so that 
it is appropriate for answering the question. Hormonal relationships during pregnancy 
will not necessarily be the same in the non-pregnant model and vice versa. 
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